

Iron-Chelating Therapy and the Treatment of Thalassaemia

Blood

89, 739-761

DOI: 10.1182/blood.v89.3.739

Citation Report

#	ARTICLE	IF	CITATIONS
1	Pathological Biomineralization of Iron. , 0, , 219-276.		2
2	Transfusion and Iron Chelation Therapy in Thalassemia and Sickle Cell Disease. , 2009, , 689-744.		2
3	Stem Cell Transplantation. , 2009, , 774-790.		0
6	DIAMOND-BLACKFAN ANEMIA. Hematology/Oncology Clinics of North America, 1997, 11, 1061-1077.	2.2	28
7	A Risk-Benefit Assessment of Iron-Chelation Therapy. Drug Safety, 1997, 17, 407-421.	3.2	85
8	Iron chelation therapy. Journal of Internal Medicine, 1997, 242, 37-41.	6.0	31
9	Limitations of Magnetic Resonance Imaging in Measurement of Hepatic Iron. Blood, 1997, 90, 4736-4742.	1.4	73
10	The Effectiveness of Deferiprone in Thalassemia. Blood, 1997, 90, 894-894.	1.4	3
11	The Effectiveness of Deferiprone in Thalassemia. Blood, 1997, 90, 894-894.	1.4	1
12	Blood transfusion in sickle cell disease. Blood Reviews, 1997, 11, 57-71.	5.7	41
13	CURRENT STATUS OF ALLOGENEIC TRANSPLANTATION FOR HAEMOGLOBINOPATHIES. British Journal of Haematology, 1997, 98, 1-7.	2.5	19
14	Immune function in patients with β^2 thalassaemia receiving the orally active iron-chelating agent deferiprone. British Journal of Haematology, 1997, 98, 597-600.	2.5	17
15	Caco-2 Cell Permeability of a New (Hydroxybenzyl)ethylenediamine Oral Iron Chelator: Correlation with Physicochemical Properties and Oral Activity. Journal of Pharmaceutical Sciences, 1998, 87, 1041-1045.	3.3	15
16	Long-Term Trials of Deferiprone in Cooley's Anemiaa. Annals of the New York Academy of Sciences, 1998, 850, 217-222.	3.8	13
17	Late Effects of Bone Marrow Transplantation for Thalassemiaa. Annals of the New York Academy of Sciences, 1998, 850, 294-299.	3.8	19
18	Iron Overload and Antioxidant Status in Patients with beta-Thalassemia Major. Annals of the New York Academy of Sciences, 1998, 850, 463-465.	3.8	11
19	Orally effective iron chelators for the treatment of iron overload disease: The case for a further look at pyridoxal isonicotinoyl hydrazone and its analogs. Translational Research, 1998, 132, 351-352.	2.3	25
20	Iron chelation therapy: The need for orally active drugs. Translational Research, 1998, 131, 290-291.	2.3	9

#	ARTICLE	IF	CITATIONS
21	Pyridoxal isonicotinoyl hydrazone and its analogs: Potential orally effective iron-chelating agents for the treatment of iron overload disease. Translational Research, 1998, 131, 306-315.	2.3	120
22	2 Juvenile haemochromatosis. Bailliere's Clinical Gastroenterology, 1998, 12, 227-235.	0.9	43
23	5 Thalassaemia: clinical management. Best Practice and Research: Clinical Haematology, 1998, 11, 147-162.	1.1	28
24	Development of iron chelators to treat iron overload disease and their use as experimental tools to probe intracellular iron metabolism. , 1998, 58, 299-305.		82
25	Iron Chelators for Thalassaemia. British Journal of Haematology, 1998, 101, 399-406.	2.5	143
26	Evaluation of cardiac status in iron-loaded thalassaemia patients following bone marrow transplantation: improvement in cardiac function during reduction in body iron burden. British Journal of Haematology, 1998, 103, 916-921.	2.5	56
28	The immunological system in hemochromatosis. Journal of Hepatology, 1998, 28, 1-7.	3.7	131
29	Long-Term Safety and Effectiveness of Iron-Chelation Therapy with Deferiprone for Thalassemia Major. New England Journal of Medicine, 1998, 339, 417-423.	27.0	389
30	Iron-Chelation Therapy with Oral Deferiprone â€” Toxicity or Lack of Efficacy?. New England Journal of Medicine, 1998, 339, 468-469.	27.0	48
32	Long-Term Trial of Deferiprone in 51 Transfusion-Dependent Iron Overloaded Patients. Blood, 1998, 91, 295-300.	1.4	191
33	Biliary Iron Excretion in Rats Following Treatment With Analogs of Pyridoxal Isonicotinoyl Hydrazone. Blood, 1998, 91, 4368-4372.	1.4	26
34	HBED: A Potential Alternative to Deferoxamine for Iron-Chelating Therapy. Blood, 1998, 91, 1446-1452.	1.4	63
35	A Multicenter Prospective Study on the Risk of Acquiring Liver Disease in Antiâ€”Hepatitis C Virus Negative Patients Affected From Homozygous Î²-Thalassemia. Blood, 1998, 92, 3460-3464.	1.4	71
36	Immunological Analysis of Î²-Thalassemic Mouse Intestinal Proteins Reveals Up-Regulation of Sucrase-Isomaltase in Response to Iron Overload. Journal of Nutrition, 1999, 129, 949-952.	2.9	2
39	A Prospective Study on TT Virus Infection in Transfusion-Dependent Patients With Î²-Thalassemia. Blood, 1999, 93, 1502-1505.	1.4	63
40	HBED: The Continuing Development of a Potential Alternative to Deferoxamine for Iron-Chelating Therapy. Blood, 1999, 93, 370-375.	1.4	46
41	The therapeutic potential of iron chelators. Expert Opinion on Investigational Drugs, 1999, 8, 2141-2158.	4.1	42
42	Decreased Sodium and Increased Transient Outward Potassium Currents in Iron-Loaded Cardiac Myocytes. Circulation, 1999, 100, 675-683.	1.6	91

#	ARTICLE	IF	CITATIONS
43	Modulation of Iron Uptake in Heart by L-Type Ca ²⁺ Channel Modifiers. Circulation Research, 1999, 84, 1302-1309.	4.5	146
44	Efficacy and Side Effects of Deferiprone (L1) in Thalassemia Patients Not Compliant with Desferrioxamine. Acta Haematologica, 1999, 101, 173-177.	1.4	24
45	Erythrocyte autoantibodies in paediatric patients with sickle cell disease receiving transfusion therapy: frequency, characteristics and significance. British Journal of Haematology, 1999, 104, 189-194.	2.5	110
46	Deferiprone therapy in homozygous human β^0 -thalassemia removes erythrocyte membrane free iron and reduces KCl cotransport activity. Translational Research, 1999, 133, 64-69.	2.3	29
47	Development of novel aroylhydrazone ligands for iron chelation therapy: 2-Pyridylcarboxaldehyde isonicotinoyl hydrazone analogs. Translational Research, 1999, 134, 510-521.	2.3	75
48	Development of Clinical Methods of Iron Deprivation for Suppression of Neoplastic and Infectious Diseases. Cancer Investigation, 1999, 17, 507-513.	1.3	27
49	Effects of C-4 Stereochemistry and C-4 α Hydroxylation on the Iron Clearing Efficiency and Toxicity of Desferrithiocin Analogues. Journal of Medicinal Chemistry, 1999, 42, 2432-2440.	6.4	56
50	The effect of prolonged iron loading on the chemical form of iron oxide deposits in rat liver and spleen. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 1999, 1454, 191-200.	3.8	10
51	Academia and industry: lessons from the unfortunate events in Toronto. Lancet, The, 1999, 353, 771-772.	13.7	52
52	Deferiprone. Drugs, 1999, 58, 553-578.	10.9	116
53	The β^0 -Thalassemias. New England Journal of Medicine, 1999, 341, 99-109.	27.0	674
55	Deferiprone, an Oral Iron Chelator, Ameliorates Experimental Colitis and Gastric Ulceration in Rats. Inflammatory Bowel Diseases, 1999, 5, 253-261.	1.9	21
56	Iron Chelation With Deferoxamine. Journal of Pediatric Hematology/Oncology, 1999, 21, 136-141.	0.6	5
57	Comparison of Cytotoxic Aldehyde Generation in Beta-Thalassemia Patients Chelated with Deferoxamine or Deferiprone (L1) Versus NO Chelation. Hematology, 1999, 4, 67-76.	1.5	18
58	Intestinal β -carotene 15,15 α -dioxygenase activity is markedly enhanced in copper-deficient rats fed on high-iron diets and fructose. British Journal of Nutrition, 2000, 84, 117-124.	2.3	22
59	Iron Overload and Iron-Chelating Therapy in Hemoglobin E- β^0 Thalassemia. The American Journal of Pediatric Hematology/oncology, 2000, 22, 593-597.	1.3	19
60	Diamond-Blackfan anemia. Current Opinion in Hematology, 2000, 7, 85-94.	2.5	64
61	Safety profile of the oral iron chelator deferiprone: a multicentre study. British Journal of Haematology, 2000, 108, 305-312.	2.5	168

#	ARTICLE	IF	CITATIONS
62	Benefits and Complications of Regular Blood Transfusion in Patients with Beta-Thalassaemia major. Vox Sanguinis, 2000, 79, 129-137.	1.5	72
63	New trends in the treatment of β^2 -thalassemia. Critical Reviews in Oncology/Hematology, 2000, 33, 105-118.	4.4	43
64	Les syndromes thalassémiques. Revue Francaise Des Laboratoires, 2000, 2000, 23-27.	0.0	2
65	The role of free radical reactions with haemoglobin and thalassaemia. Journal of Inorganic Biochemistry, 2000, 79, 327-329.	3.5	6
66	Congenital bone marrow failure syndromes. British Journal of Haematology, 2000, 111, 30-42.	2.5	4
67	Venous thromboembolism and hypercoagulability in splenectomized patients with thalassaemia intermedia. British Journal of Haematology, 2000, 111, 467-473.	2.5	157
68	Oral iron chelation therapy for thalassaemia: an uncertain scene. British Journal of Haematology, 2000, 111, 2-5.	2.5	7
69	Iron chelation therapy. Reviews in Clinical and Experimental Hematology, 2000, 4, 337-361.	0.1	12
70	First human studies with a high-molecular-weight iron chelator. Translational Research, 2000, 135, 57-65.	2.3	56
71	Fast biological iron chelators: kinetics of iron removal from human diferric transferrin by multidentate hydroxypyridonates. Journal of Biological Inorganic Chemistry, 2000, 5, 634-641.	2.6	70
72	Epidemiological situation and treatment of patients with thalassemia major in Germany: results of the German multicenter β^2 -thalassemia study. Annals of Hematology, 2000, 79, 7-12.	1.8	28
73	Effect of poly(hydroxamic acids) as chelating agents on iron metabolism in animals with hemochromatosis. Pharmaceutical Chemistry Journal, 2000, 34, 234-236.	0.8	0
74	Severity of iron overload in patients with sickle cell disease receiving chronic red blood cell transfusion therapy. Blood, 2000, 96, 76-79.	1.4	177
75	Erythropoietin, iron, and erythropoiesis. Blood, 2000, 96, 823-833.	1.4	317
76	Safety and efficacy of subcutaneous bolus injection of deferoxamine in adult patients with iron overload. Blood, 2000, 95, 2776-2779.	1.4	81
77	Long-term outcome of continuous 24-hour deferoxamine infusion via indwelling intravenous catheters in high-risk β^2 -thalassemia. Blood, 2000, 95, 1229-1236.	1.4	259
78	Chelation therapy in iron overload. , 2000, , 339-354.		3
79	Thalassemias and their interactions with hemochromatosis. , 2000, , 435-441.		9

#	ARTICLE	IF	CITATIONS
80	Iron overload in sideroblastic and other nonthalassemic anemias. , 2000, , 442-452.		4
81	Systemic Oxygen-Free Radical Production in Iron-Loaded Mice. Western Journal of Nursing Research, 2000, 22, 927-935.	1.4	10
82	The use of skin Fe levels as a surrogate marker for organ Fe levels, to monitor treatment in cases of iron overload. Physics in Medicine and Biology, 2000, 45, 1387-1396.	3.0	21
83	Hepatic Iron Concentration and Total Body Iron Stores in Thalassemia Major. New England Journal of Medicine, 2000, 343, 1656-1657.	27.0	3
84	Improving the Oral Bioavailability of the Iron Chelator HBED by Breaking the Symmetry of the Intramolecular H-Bond Network. Journal of Medicinal Chemistry, 2000, 43, 1467-1475.	6.4	30
85	Factors Influencing Effectiveness of Deferiprone in a Thalassaemia major Clinical Setting. Acta Haematologica, 2000, 104, 99-102.	1.4	33
86	Changes in Gene Expression with Iron Loading and Chelation in Cardiac Myocytes and Non-myocytic Fibroblasts. Journal of Molecular and Cellular Cardiology, 2000, 32, 233-246.	1.9	44
87	Deferiprone for thalassaemia. Lancet, The, 2000, 356, 1444-1445.	13.7	9
88	Audiological evaluation in adult beta-thalassemia major patients under regular chelation treatment. Pharmacological Research, 2000, 42, 485-487.	7.1	24
90	Diamondâ€“Blackfan anaemia. Best Practice and Research in Clinical Haematology, 2000, 13, 391-406.	1.7	22
91	Liver Iron Estimation in β^2 -thalassaemia: Comparison of MRI Biochemical Assay and Histological Grading. Clinical Radiology, 2001, 56, 911-916.	1.1	21
92	Impact of chronic transfusion on incidence of pain and acute chest syndrome during the Stroke Prevention Trial (STOP) in sickle-cell anemia. Journal of Pediatrics, 2001, 139, 785-789.	1.8	204
93	Development of potential iron chelators for the treatment of Friedreichâ€™s ataxia: ligands that mobilize mitochondrial iron. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2001, 1536, 133-140.	3.8	80
95	Chelation therapy in β^2 -thalassemia: An optimistic update. Seminars in Hematology, 2001, 38, 360-366.	3.4	108
96	Noninvasive methods for quantitative assessment of transfusional iron overload in sickle cell disease. Seminars in Hematology, 2001, 38, 37-56.	3.4	62
97	Progression of iron overload in sickle cell disease. Seminars in Hematology, 2001, 38, 57-62.	3.4	105
98	Iron chelation: New therapies. Seminars in Hematology, 2001, 38, 73-76.	3.4	14
99	Anemias por defectos congÃ©nitos de la hemoglobina. hemoglobinopatÃ­as estructurales y talasemias. Medicine, 2001, 8, 2684-2693.	0.0	4

#	ARTICLE	IF	CITATIONS
100	Stroke in Children With Sickle Cell Anaemia. Paediatric Drugs, 2001, 3, 421-432.	3.1	16
102	Endocrine complications of thalassemia. Journal of Endocrinological Investigation, 2001, 24, 716-723.	3.3	37
103	Diagnosing myocardial iron overload. European Heart Journal, 2001, 22, 2140-2141.	2.2	27
104	Selenium and Glutathione Peroxidase With Beta-Thalassemia Major. Nursing Research, 2001, 50, 178-183.	1.7	22
105	Intraerythrocytic Iron Chelation: A New Therapy for Thalassemia?. Hematology, 2001, 6, 73-89.	1.5	7
106	Secondary Iron Overload. Hematology American Society of Hematology Education Program, 2001, 2001, 47-61.	2.5	188
107	Unprecedented oxidation of a biologically active aroylhydrazone chelator catalysed by iron(III): serendipitous identification of diacylhydrazine ligands with high iron chelation efficacy. Journal of Biological Inorganic Chemistry, 2001, 6, 801-809.	2.6	48
108	Practical management of iron overload. British Journal of Haematology, 2001, 115, 239-252.	2.5	317
109	3-Hydroxy-(4 H)-benzopyran-4-ones as potential iron chelating agents in vivo. Bioorganic and Medicinal Chemistry, 2001, 9, 3041-3047.	3.0	40
110	Î²-Carotene 15,15â€²-Dioxygenase activity in human tissues and cells: evidence of an iron dependency. Journal of Nutritional Biochemistry, 2001, 12, 640-647.	4.2	35
111	Genotoxicity of iron chelators in L5178Y mouse lymphoma cells. Environmental and Molecular Mutagenesis, 2001, 38, 347-356.	2.2	17
112	The Effects of Cardiac Myocytes on Interstitial Fibroblasts in Toxic Iron Overload. Cardiovascular Toxicology, 2001, 1, 299-308.	2.7	7
113	The controversial role of deferiprone in the treatment of thalassemia. Translational Research, 2001, 137, 324-329.	2.3	41
114	Long-term administration of high-dose deferoxamine 2 days per week in thalassemic patients. European Journal of Haematology, 2001, 67, 230-231.	2.2	5
115	Comparison between deferoxamine and deferiprone (L1) in ironâ€loaded thalassemia patients. European Journal of Haematology, 2001, 67, 30-34.	2.2	55
116	Increased Release of Arachidonic Acid and Eicosanoids in Iron-Overloaded Cardiomyocytes. Circulation, 2001, 103, 2395-2401.	1.6	25
117	Dofetilide: what role in the treatment of ventricular tachyarrhythmias?. European Heart Journal, 2001, 22, 2141-2143.	2.2	6
118	Abnormal Glucose Tolerance in Transfusion-Dependent ÂThalassemic Patients. Diabetes Care, 2001, 24, 850-854.	8.6	77

#	ARTICLE	IF	CITATIONS
119	Decreasing Effects of Iron Toxicosis on Selenium and Glutathione Peroxidase Activity. Western Journal of Nursing Research, 2002, 24, 119-131.	1.4	7
120	Protect the unborn child. Archives of Disease in Childhood, 2002, 86, 347-347.	1.9	0
121	Blood Letting in High-Ferritin Type 2 Diabetes. Diabetes, 2002, 51, 1000-1004.	0.6	313
122	The heart in thalassaemia. European Heart Journal, 2002, 23, 102-105.	2.2	19
123	Submental intubation in a patient with beta-thalassaemia major undergoing elective maxillary and mandibular osteotomies. British Journal of Anaesthesia, 2002, 88, 288-291.	3.4	41
124	Unrelated donor bone marrow transplantation for thalassemia: the effect of extended haplotypes. Blood, 2002, 99, 4350-4356.	1.4	124
125	HBED ligand: preclinical studies of a potential alternative to deferoxamine for treatment of chronic iron overload and acute iron poisoning. Blood, 2002, 99, 3019-3026.	1.4	40
126	Hypoparathyroidism in Transfusion-Dependent Patients With β^0 -Thalassemia. Journal of Pediatric Hematology/Oncology, 2002, 24, 291-293.	0.6	21
128	The influence of deferiprone (L1) and deferoxamine on iron and essential element tissue level and parameters of oxidative status in dietary iron-loaded mice. Toxicology Letters, 2002, 128, 169-175.	0.8	28
129	Structure-Activity Relationships Among Desazadesferrithiocin Analogues. Advances in Experimental Medicine and Biology, 2002, 509, 167-184.	1.6	9
130	Monitoring chelation therapy to achieve optimal outcome in the treatment of thalassaemia. Best Practice and Research in Clinical Haematology, 2002, 15, 329-368.	1.7	42
131	Bone marrow failure syndromes in children. Pediatric Clinics of North America, 2002, 49, 973-988.	1.8	54
132	Liver disease in transfusion dependent thalassaemia major. Archives of Disease in Childhood, 2002, 86, 344-347.	1.9	44
133	Deferiprone: greater efficacy at depleting myocardial than hepatic iron?. Lancet, The, 2002, 360, 501-502.	13.7	8
134	Repeated fMRI Using Iron Oxide Contrast Agent in Awake, Behaving Macaques at 3 Tesla. NeuroImage, 2002, 16, 283-294.	4.2	250
135	Juvenile hemochromatosis. Seminars in Hematology, 2002, 39, 242-248.	3.4	78
136	The management of haemoglobinopathies. Current Paediatrics, 2002, 12, 290-297.	0.2	2
137	Thalassemia: current approach to an old disease. Pediatric Clinics of North America, 2002, 49, 1165-1191.	1.8	41

#	ARTICLE	IF	CITATIONS
138	Diseases of iron metabolism. Pediatric Clinics of North America, 2002, 49, 893-909.	1.8	13
139	Sickle cell disease. Pediatric Clinics of North America, 2002, 49, 1193-1210.	1.8	44
140	Anemias Sideroblásticas. Gaceta Medica De Bilbao, 2002, 99, 44-48.	0.0	0
141	Design, Synthesis, and Physicochemical and Biological Characterization of a New Iron Chelator of the Family of Hydroxychromenes. Journal of Medicinal Chemistry, 2002, 45, 5776-5785.	6.4	12
142	Ethical Issues During and After the Study. , 2002, , 113-169.		0
143	Urinary iron excretion induced by intravenous infusion of deferoxamine in α -thalassemia homozygous patients. Brazilian Journal of Medical and Biological Research, 2002, 35, 1319-1328.	1.5	14
144	Bimodal cardiac dysfunction in an animal model of iron overload. Translational Research, 2002, 140, 263-271.	2.3	29
145	Mobilization of intracellular iron by analogs of pyridoxal isonicotinoyl hydrazone (PIH) is determined by the membrane permeability of the iron-chelator complexes. Biochemical Pharmacology, 2002, 64, 1689-1701.	4.4	28
146	Evaluation of iron overload by single voxel MRS measurement of liver T2. Journal of Magnetic Resonance Imaging, 2002, 15, 395-400.	3.4	55
147	Bone marrow transplantation for hematological disorders—Shiraz experience. Indian Journal of Pediatrics, 2002, 69, 31-32.	0.8	3
148	Iron chelators as therapeutic agents for the treatment of cancer. Critical Reviews in Oncology/Hematology, 2002, 42, 267-281.	4.4	189
149	Guidelines for assessing appropriateness of pediatric transfusion. Transfusion, 2002, 42, 1398-1413.	1.6	204
150	Estimates of the effect on hepatic iron of oral deferiprone compared with subcutaneous desferrioxamine for treatment of iron overload in thalassemia major: a systematic review. BMC Hematology, 2002, 2, 4.	2.6	16
151	Natural history of juvenile haemochromatosis. British Journal of Haematology, 2002, 117, 973-979.	2.5	145
152	The safety and effectiveness of deferiprone in a large-scale, 3-year study in Italian patients. British Journal of Haematology, 2002, 118, 330-336.	2.5	192
153	Orally active iron chelators. Blood Reviews, 2002, 16, 127-134.	5.7	12
154	SQUID biosusceptometry in the measurement of hepatic iron. Pediatric Radiology, 2003, 33, 373-377.	2.0	30
155	Safety monitoring of cardiac and hepatic systems in β -thalassemia patients with chelating treatment in Taiwan*. European Journal of Haematology, 2003, 70, 392-397.	2.2	54

#	ARTICLE	IF	CITATIONS
156	Lipophilicity of analogs of pyridoxal isonicotinoyl hydrazone (PIH) determines the efflux of iron complexes and toxicity in K562 cells. <i>Biochemical Pharmacology</i> , 2003, 65, 349-360.	4.4	36
157	Deferoxamine prevents cardiac hypertrophy and failure in the gerbil model of iron-induced cardiomyopathy. <i>Translational Research</i> , 2003, 142, 332-340.	2.3	24
158	Iron chelators for the treatment of iron overload disease: Relationship between structure, redox activity, and toxicity. <i>American Journal of Hematology</i> , 2003, 73, 200-210.	4.1	153
159	Iron chelation promoted by desazadesferrithiocin analogs: An enantioselective barrier. <i>Chirality</i> , 2003, 15, 593-599.	2.6	15
160	Total synthesis and structure revision of petrobactin. <i>Tetrahedron</i> , 2003, 59, 2007-2014.	1.9	68
161	Iron chelators and iron toxicity. <i>Alcohol</i> , 2003, 30, 151-158.	1.7	46
162	Screening strategies in c282y-linked haemochromatosis. <i>British Journal of Haematology</i> , 2003, 120, 1089-1090.	2.5	0
163	The dangers of iron overload in pyruvate kinase deficiency. <i>British Journal of Haematology</i> , 2003, 120, 1090-1091.	2.5	20
164	Photosensitization in chronic myelogenous leukaemia patients treated with imatinib mesylate. <i>British Journal of Haematology</i> , 2003, 120, 1091-1092.	2.5	35
165	Successful combination of anti-cd33 antibody (gemtuzumab ozogamicin) and minimal conditioning before second allografting in recurrent acute myeloid leukaemia. <i>British Journal of Haematology</i> , 2003, 120, 1093-1094.	2.5	4
166	Methylenetetrahydrofolate reductase 677cc normal genotype may protect against multiple myeloma. <i>British Journal of Haematology</i> , 2003, 120, 1094-1094.	2.5	6
167	Reply to Yanamandra et al. <i>British Journal of Haematology</i> , 2003, 120, 1096-1096.	2.5	0
168	Identification of the di-pyridyl ketone isonicotinoyl hydrazone (PKIH) analogues as potent iron chelators and anti-tumour agents. <i>British Journal of Pharmacology</i> , 2003, 138, 819-830.	5.4	94
170	Cardiac complications in thalassemia: noninvasive detection methods and new directions in the clinical management. <i>Expert Review of Cardiovascular Therapy</i> , 2003, 1, 439-452.	1.5	8
171	Methoxylation of Desazadesferrithiocin Analogues: Enhanced Iron Clearing Efficiency. <i>Journal of Medicinal Chemistry</i> , 2003, 46, 1470-1477.	6.4	37
172	Differential accumulation of non-transferrin-bound iron by cardiac myocytes and fibroblasts. <i>Journal of Molecular and Cellular Cardiology</i> , 2003, 35, 505-514.	1.9	37
173	Cardiac failure after initiation of insulin treatment in diabetic patients with β^2 -thalassemia major. <i>Journal of Pediatrics</i> , 2003, 143, 541-542.	1.8	4
174	β^2 -Thalassaemia: emergence of new and improved iron chelators for treatment. <i>International Journal of Biochemistry and Cell Biology</i> , 2003, 35, 1144-1149.	2.8	32

#	ARTICLE	IF	CITATIONS
175	Inappropriate Leptin Secretion in Thalassemia: A Potential Cofactor of Pubertal Timing Derangement. Journal of Pediatric Endocrinology and Metabolism, 2003, 16, 877-81.	0.9	14
176	Safety, Tolerability, and Pharmacokinetics of ICL670, a New Orally Active Iron-Chelating Agent in Patients with Transfusion-Dependent Iron Overload Due to β^2 -Thalassemia. Journal of Clinical Pharmacology, 2003, 43, 565-572.	2.0	131
177	Desferrithiocin Analogue Based Hexacoordinate Iron(III) Chelators. Journal of Medicinal Chemistry, 2003, 46, 16-24.	6.4	24
178	Pathophysiology and Treatment of Iron Overload in Thalassemia Patients In Tropical Countries. Advances in Experimental Medicine and Biology, 2003, 531, 57-68.	1.6	5
179	Siderophores and Transferrins. , 2003, , 141-168.		14
180	Role of deferiprone in chelation therapy for transfusional iron overload. Blood, 2003, 102, 17-24.	1.4	210
181	Current and future therapy in haemochromatosis and Wilson's disease. Expert Opinion on Pharmacotherapy, 2003, 4, 2239-2251.	1.8	7
182	Friedreich's ataxia: iron chelators that target the mitochondrion as a therapeutic strategy?. Expert Opinion on Investigational Drugs, 2003, 12, 235-245.	4.1	63
184	Relationship between hepatocellular injury and transfusional iron overload prior to and during iron chelation with desferrioxamine: a study in adult patients with acquired anemias. Blood, 2003, 101, 91-96.	1.4	108
185	Safety and effectiveness of long-term therapy with the oral iron chelator deferiprone. Blood, 2003, 102, 1583-1587.	1.4	284
186	Diagnosis of Hereditary Haemochromatosis using Non-Invasive Methods. Transfusion Medicine and Hemotherapy, 2003, 30, 27-36.	1.6	7
187	The correlation between ferritin level and cardiac dysfunction in patients with thalassemia. Paediatrica Indonesiana, 2003, 43, 24.	0.1	0
188	Erythropoietic Disorders Involving Heme Biosynthesis. , 2003, , 1-21.		2
189	Objectives and Methods of Iron Chelation Therapy. Bioinorganic Chemistry and Applications, 2003, 1, 151-168.	4.1	25
190	Hemoglobinopathies. , 2004, , 209-220.		0
191	Antioxidant Capacity in Seminal Plasma of Transfusion-Dependent β^2 -Thalassemic Patients. Experimental and Clinical Endocrinology and Diabetes, 2004, 112, 131-134.	1.2	20
192	CLINICAL EVALUATION OF THE ORAL IRON CHELATOR DEFERIPRONE FOR THE POTENTIAL TREATMENT OF IRON OVERLOAD IN BIRD SPECIES. Journal of Zoo and Wildlife Medicine, 2004, 35, 40-49.	0.6	15
193	The effects of desferrioxamine on cisplatin-induced lipid peroxidation and the activities of antioxidant enzymes in rat kidneys. Human and Experimental Toxicology, 2004, 23, 29-34.	2.2	89

#	ARTICLE	IF	CITATIONS
194	Five-Year Trial of Deferiprone Chelation Therapy in Thalassaemia major Patients. <i>Acta Haematologica</i> , 2004, 112, 179-183.	1.4	21
195	Iron-chelation therapy: an update. <i>The Hematology Journal</i> , 2004, 5, 287-292.	1.4	39
196	Unexpectedly high but still asymptomatic iron overload in a patient with pyruvate kinase deficiency. <i>The Hematology Journal</i> , 2004, 5, 543-545.	1.4	12
197	Evaluation of iron overload. <i>British Journal of Haematology</i> , 2004, 124, 697-711.	2.5	103
198	Purging iron from the heart. <i>British Journal of Haematology</i> , 2004, 125, 545-551.	2.5	34
199	Magnetic resonance imaging in the evaluation of iron overload in patients with beta thalassaemia and sickle cell disease. <i>British Journal of Haematology</i> , 2004, 126, 736-742.	2.5	131
200	Brittenham et al response. <i>Translational Research</i> , 2004, 143, 133-134.	2.3	0
201	Acyclonucleoside Iron Chelators of 1â€(2â€Hydroxyethoxy)methylâ€2â€alkylâ€3â€hydroxyâ€4â€pyridinones: Potential Oral Iron Chelation Therapeutics. <i>Nucleosides, Nucleotides and Nucleic Acids</i> , 2004, 23, 599-611.	1.1	12
202	Novel Chelators for Central Nervous System Disorders That Involve Alterations in the Metabolism of Iron and Other Metal Ions. <i>Annals of the New York Academy of Sciences</i> , 2004, 1012, 326-341.	3.8	103
203	Magnetic resonance screening of iron status in transfusion-dependent β^2 -thalassaemia patients. <i>British Journal of Haematology</i> , 2004, 124, 385-390.	2.5	48
204	Unrelated peripheral blood and cord blood hematopoietic stem cell transplants for thalassemia major. <i>American Journal of Hematology</i> , 2004, 75, 209-212.	4.1	12
205	Adherence to deferoxamine therapy: Heeding Hippocrates and Osler. <i>American Journal of Hematology</i> , 2004, 76, 415-416.	4.1	7
206	Mimicking liver iron overload using liposomal ferritin preparations. <i>Magnetic Resonance in Medicine</i> , 2004, 51, 607-611.	3.0	50
207	Hematologic problems in immigrants from Southeast Asia. <i>Hematology/Oncology Clinics of North America</i> , 2004, 18, 1405-1422.	2.2	13
208	Anemias hemolíticas. <i>Anales De Pediatría Continuada</i> , 2004, 2, 12-21.	0.1	0
209	Hydroxamate-Based Iron Chelators: A Combinatorial Syntheses of Desferrioxamine B Analogues and Evaluation of Binding Affinities. <i>ACS Combinatorial Science</i> , 2004, 6, 239-254.	3.3	34
210	PCTH: a novel orally active chelator of the aroylhydrazone class that induces iron excretion from mice. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2004, 1739, 70-80.	3.8	23
211	Combined Therapy With Desferrioxamine and Deferiprone: A New Protocol for Iron Chelation in Thalassemia. <i>Journal of Pediatric Hematology/Oncology</i> , 2004, 26, 451-453.	0.6	14

#	ARTICLE	IF	CITATIONS
212	Anemias: A Clinical Laboratory Perspective. Laboratory Medicine, 2004, 35, 177-185.	1.2	5
213	Myocardial iron loading in transfusion-dependent thalassemia and sickle cell disease. Blood, 2004, 103, 1934-1936.	1.4	315
214	Complications of β^2 -thalassemia major in North America. Blood, 2004, 104, 34-39.	1.4	403
215	Safety and efficacy of subcutaneous bolus injection of deferoxamine in adult patients with iron overload: an update. Blood, 2004, 103, 747-748.	1.4	30
216	Autologous hematopoietic stem cell transplantation for severe/refractory intestinal Behcet disease. Blood, 2004, 103, 748-750.	1.4	44
218	Desferrioxamine mesylate for managing transfusional iron overload in people with transfusion-dependent thalassaemia. , 2005, , CD004450.		18
219	Noninvasive measurement and imaging of liver iron concentrations using proton magnetic resonance. Blood, 2005, 105, 855-861.	1.4	799
220	Intracellular labile iron pools as direct targets of iron chelators: a fluorescence study of chelator action in living cells. Blood, 2005, 106, 3242-3250.	1.4	220
221	Unrelated Bone Marrow Transplantation for β^2 -Thalassemia Patients: The Experience of the Italian Bone Marrow Transplant Group. Annals of the New York Academy of Sciences, 2005, 1054, 186-195.	3.8	135
222	Treatment of Hepatitis C Virus Infection in Thalassemia. Annals of the New York Academy of Sciences, 2005, 1054, 290-299.	3.8	20
223	Monitoring Long-Term Efficacy of Iron Chelation Treatment with Biomagnetic Liver Susceptometry. Annals of the New York Academy of Sciences, 2005, 1054, 350-357.	3.8	57
224	Measurement and Mapping of Liver Iron Concentrations Using Magnetic Resonance Imaging. Annals of the New York Academy of Sciences, 2005, 1054, 379-385.	3.8	96
225	Physiology and Pathophysiology of Iron Cardiomyopathy in Thalassemia. Annals of the New York Academy of Sciences, 2005, 1054, 386-395.	3.8	119
226	Quality of Life in Patients with Thalassemia Intermedia Compared to Thalassemia Major. Annals of the New York Academy of Sciences, 2005, 1054, 457-461.	3.8	80
227	A Simple Model to Assess and Improve Adherence to Iron Chelation Therapy with Deferoxamine in Patients with Thalassemia. Annals of the New York Academy of Sciences, 2005, 1054, 486-491.	3.8	14
228	Desferrioxamine release from gelatin-based systems. Biotechnology and Applied Biochemistry, 2005, 42, 237.	3.1	12
229	Psychosocial implications of Thalassemia Major. Pediatrics International, 2005, 47, 84-89.	0.5	63
230	Effects of dietary baicalin supplementation on iron overload-induced mouse liver oxidative injury. European Journal of Pharmacology, 2005, 509, 195-200.	3.5	90

#	ARTICLE	IF	CITATIONS
231	Mobilization of iron from cells by hydroxyquinoline-based chelators. <i>Biochemical Pharmacology</i> , 2005, 71, 214-222.	4.4	11
232	Safety of oral iron chelator deferiprone in young thalassaemics. <i>European Journal of Haematology</i> , 2005, 74, 217-220.	2.2	44
233	Comparison of organ dysfunction in transfused patients with SCD or β^0 thalassemia. <i>American Journal of Hematology</i> , 2005, 80, 70-74.	4.1	125
234	Mechanisms of tissue-iron relaxivity: Nuclear magnetic resonance studies of human liver biopsy specimens. <i>Magnetic Resonance in Medicine</i> , 2005, 54, 1185-1193.	3.0	87
235	Liver volume in thalassaemia major: relationship with body weight, serum ferritin, and liver function. <i>Pediatric Radiology</i> , 2005, 35, 165-168.	2.0	5
236	Deferiprone as an oral iron chelator in sickle cell disease. <i>Annals of Hematology</i> , 2005, 84, 434-440.	1.8	36
237	Recent acquisitions in the management of iron overload. <i>Annals of Hematology</i> , 2005, 84, 640-645.	1.8	9
238	Pathogenetic mechanisms underlying myelodysplastic syndromes. , 2005, , 63-94.		3
239	Supportive care in myelodysplastic syndromes: hemopoietic cytokine and iron chelation therapy. , 2005, , 209-242.		3
240	Cardiac Iron Determines Cardiac T2*, T2, and T1 in the Gerbil Model of Iron Cardiomyopathy. <i>Circulation</i> , 2005, 112, 535-543.	1.6	212
241	Spectrum of β^0 -Globin Gene Mutations Among Thalassemia Patients in the West Bank Region of Palestine. <i>Hemoglobin</i> , 2005, 29, 119-132.	0.8	7
242	Liver iron concentration and fibrosis in a cohort of transfusion-dependent patients on long-term desferrioxamine therapy. <i>The Hematology Journal</i> , 2005, 5, 572-578.	1.4	19
243	1/T2 and Magnetic Susceptibility Measurements in a Gerbil Cardiac Iron Overload Model. <i>Radiology</i> , 2005, 234, 749-755.	7.3	20
244	Intensification of Chelating-Therapy in Patients with Thalassemia major. <i>Klinische Padiatrie</i> , 2005, 217, 120-125.	0.6	3
245	Iron Stores, Blood Donation, and Insulin Sensitivity and Secretion. <i>Clinical Chemistry</i> , 2005, 51, 1201-1205.	3.2	131
247	pectrum of β^0 -Globin Gene Mutations Among Thalassemia Patients in the West Bank Region of Palestine. <i>Hemoglobin</i> , 2005, 29, 119-132.	0.8	21
248	Chronic zinc toxicity in an infant who received zinc therapy for atopic dermatitis. <i>Acta Paediatrica, International Journal of Paediatrics</i> , 2005, 94, 1333-1335.	1.5	11
249	Polyamine-Vectored Iron Chelators:Â The Role of Charge. <i>Journal of Medicinal Chemistry</i> , 2005, 48, 4120-4137.	6.4	21

#	ARTICLE	IF	CITATIONS
250	Treating iron overload: The state of the art. Seminars in Hematology, 2005, 42, S2-S4.	3.4	8
251	Monitoring and treatment of iron overload: State of the art and new approaches. Seminars in Hematology, 2005, 42, S14-S18.	3.4	26
252	Iron overload in thalassemia and sickle cell disease. Seminars in Hematology, 2005, 42, S5-S9.	3.4	22
253	Pulmonary Hypertension in Sickle Cell Disease: Mechanisms, Diagnosis, and Management. Hematology/Oncology Clinics of North America, 2005, 19, 881-896.	2.2	68
254	Management of pregnancy in a patient with β^0 thalassaemia major. International Journal of Obstetric Anesthesia, 2005, 14, 351-354.	0.4	16
255	Nanoparticle and other metal chelation therapeutics in Alzheimer disease. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2005, 1741, 246-252.	3.8	142
256	Iron-chelating therapy with the new oral agent ICL670 (Exjade®). Best Practice and Research in Clinical Haematology, 2005, 18, 289-298.	1.7	78
257	HypersidÃ©roses de l'enfant. EMC - PÃ©diatrie, 2005, 2, 296-302.	0.0	4
258	MRI R2 and R2* mapping accurately estimates hepatic iron concentration in transfusion-dependent thalassemia and sickle cell disease patients. Blood, 2005, 106, 1460-1465.	1.4	894
259	The Evolution of Iron Chelators for the Treatment of Iron Overload Disease and Cancer. Pharmacological Reviews, 2005, 57, 547-583.	16.0	641
260	Partition-Variant Desferrithiocin Analogues:â€” Organ Targeting and Increased Iron Clearance. Journal of Medicinal Chemistry, 2005, 48, 821-831.	6.4	19
261	Iron-Chelating and Free-Radical Scavenging Activities of Microwave-Processed Green Tea in Iron Overload. Hemoglobin, 2006, 30, 311-327.	0.8	39
262	Thalassemias. , 0, , 281-301.		2
263	A Randomized Controlled Study Evaluating the Safety and Efficacy of Deferiprone Treatment in Thalassemia Major Patients from Hong Kong. Hemoglobin, 2006, 30, 263-274.	0.8	37
264	PCTH: A Novel Orally Active Chelator for the Treatment of Iron Overload Disease. Hemoglobin, 2006, 30, 93-104.	0.8	9
265	Diamond Blackfan Anemia: New Paradigms for a â€œNot So Pureâ€”Inherited Red Cell Aplasia. Seminars in Hematology, 2006, 43, 167-177.	3.4	32
267	β^0 -Thalassemia: the Lebanese experience. International Journal of Laboratory Hematology, 2006, 28, 217-227.	0.2	28
268	Deferasirox and deferiprone remove cardiac iron in the iron-overloaded gerbil. Translational Research, 2006, 148, 272-280.	5.0	69

#	ARTICLE	IF	CITATIONS
269	Deferasirox—An Oral Agent for Chronic Iron Overload. <i>Annals of Pharmacotherapy</i> , 2006, 40, 1110-1117.	1.9	52
270	(S)-4,5-Dihydro-2-(2-hydroxy-4-hydroxyphenyl)-4-methyl-4-thiazolecarboxylic Acid Polyethers: A Solution to Nephrotoxicity. <i>Journal of Medicinal Chemistry</i> , 2006, 49, 2772-2783.	6.4	22
271	Thalassemia intermedia: Revisited. <i>Blood Cells, Molecules, and Diseases</i> , 2006, 37, 12-20.	1.4	269
272	Nanoparticle iron chelators: A new therapeutic approach in Alzheimer disease and other neurologic disorders associated with trace metal imbalance. <i>Neuroscience Letters</i> , 2006, 406, 189-193.	2.1	172
273	The Design, Synthesis, and Evaluation of Organ-Specific Iron Chelators. <i>Journal of Medicinal Chemistry</i> , 2006, 49, 7032-7043.	6.4	21
274	Infusion of Autologous Retrodifferentiated Stem Cells into Patients with Beta-Thalassemia. <i>Scientific World Journal</i> , The, 2006, 6, 1278-1297.	2.1	4
275	Action of chelators in iron-loaded cardiac cells: accessibility to intracellular labile iron and functional consequences. <i>Blood</i> , 2006, 108, 3195-3203.	1.4	178
276	A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia. <i>Blood</i> , 2006, 107, 3455-3462.	1.4	636
277	Oral chelators deferasirox and deferiprone for transfusional iron overload in thalassemia major: new data, new questions. <i>Blood</i> , 2006, 107, 3436-3441.	1.4	272
278	The quest for the normal hemoglobin concentration. <i>Blood</i> , 2006, 108, 777-778.	1.4	7
279	Does liver biopsy overestimate liver iron concentration?. <i>Blood</i> , 2006, 108, 778-778.	1.4	9
280	Does liver biopsy overestimate liver iron concentration?. <i>Blood</i> , 2006, 108, 1775-1776.	1.4	16
281	The Hoechst low-fluorescent profile of the side population: clonogenicity versus dye retention. <i>Blood</i> , 2006, 108, 1774-1775.	1.4	5
283	Correlative Study of Iron Accumulation in Liver, Myocardium, and Pituitary Assessed With MRI in Young Thalassemic Patients. <i>Journal of Pediatric Hematology/Oncology</i> , 2006, 28, 311-315.	0.6	53
284	Myelodysplastic Syndromes: Iron Overload Consequences and Current Chelating Therapies. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2006, 4, 91-96.	4.9	77
285	Survival in Thalassaemia Major Patients Prognostic Value of Doppler-Demonstrated Left Ventricular Restrictive Filling Pattern. <i>Circulation Journal</i> , 2006, 70, 1037-1042.	1.6	24
286	Iron chelators may help prevent photoaging. <i>Journal of Cosmetic Dermatology</i> , 2006, 5, 210-217.	1.6	21
287	Downregulation of hepcidin and haemojuvelin expression in the hepatocyte cell-line HepG2 induced by thalassaemic sera. <i>British Journal of Haematology</i> , 2006, 135, 129-138.	2.5	73

#	ARTICLE	IF	CITATIONS
288	Oxachelin, a Novel Iron Chelator and Antifungal Agent from Streptomyces sp. GW9/1258. Journal of Antibiotics, 2006, 59, 659-663.	2.0	35
289	Iron-loaded cardiac myocytes stimulate cardiac myofibroblast DNA synthesis. Molecular and Cellular Biochemistry, 2006, 281, 77-85.	3.1	11
290	Dietary supplementation of baicalin and quercetin attenuates iron overload induced mouse liver injury. European Journal of Pharmacology, 2006, 535, 263-269.	3.5	76
291	Neurophysiologic and intellectual evaluation of beta-thalassemia patients. Brain and Development, 2006, 28, 14-18.	1.1	40
292	Iron: A New Target for Pharmacological Intervention in Neurodegenerative Diseases. Seminars in Pediatric Neurology, 2006, 13, 186-197.	2.0	105
293	Multislice multiecho T2* cardiovascular magnetic resonance for detection of the heterogeneous distribution of myocardial iron overload. Journal of Magnetic Resonance Imaging, 2006, 23, 662-668.	3.4	173
294	mRNA expression of iron regulatory genes in β^2 -thalassemia intermedia and β^2 -thalassemia major mouse models. American Journal of Hematology, 2006, 81, 479-483.	4.1	65
295	Chelators at the Cancer Coalface: Desferrioxamine to Triapine and Beyond. Clinical Cancer Research, 2006, 12, 6876-6883.	7.0	178
296	The prevention and management of stroke in sickle cell anaemia. Expert Opinion on Biological Therapy, 2006, 6, 1087-1098.	3.1	12
297	Iron chelators as therapeutic iron depletion agents. Expert Opinion on Therapeutic Patents, 2006, 16, 1533-1556.	5.0	32
299	Transfusion of the Hemoglobinopathy Patient. , 2007, , 523-538.		4
300	Febrile, Allergic, and Other Noninfectious Transfusion Reactions. , 2007, , 677-690.		1
301	Recent Developments in Iron Chelation Therapy. Klinische Padiatrie, 2007, 219, 158-165.	0.6	31
302	A Widespread Deferoxamineâ€Mediated Ironâ€Uptake System in <i>Vibrio vulnificus</i> . Journal of Infectious Diseases, 2007, 196, 1537-1545.	4.0	44
303	Iron Storage Disorders. , 2007, , 661-676.		2
304	Urinary Iron Excretion in Young Thalassemic Patients Receiving Combined Chelation Treatment With Deferoxamine and Deferiprone. Journal of Pediatric Hematology/Oncology, 2007, 29, 598-601.	0.6	9
305	Diagnostic and Therapeutic Challenges. Retina, 2007, 27, 642-647.	1.7	2
306	Magnetic resonance imaging measurement of iron overload. Current Opinion in Hematology, 2007, 14, 183-190.	2.5	200

#	ARTICLE	IF	CITATIONS
307	Brain natriuretic peptide as marker of myocardial iron load in β^2 -thalassemia. International Journal of Cardiology, 2007, 118, 408-409.	1.7	8
308	Evaluation of Iron Levels to Avoid the Clinical Sequelae of Iron Overload. Seminars in Hematology, 2007, 44, S2-S6.	3.4	4
309	Oral deferiprone for iron chelation in people with thalassaemia. , 2007, , CD004839.		36
310	Future of ToxicologyIron Chelators and Differing Modes of Action and Toxicity:â€‰ The Changing Face of Iron Chelation Therapy. Chemical Research in Toxicology, 2007, 20, 715-720.	3.3	125
311	A randomized controlled 1-year study of daily deferiprone plus twice weekly desferrioxamine compared with daily deferiprone monotherapy in patients with thalassemia major. Haematologica, 2007, 92, 1599-1606.	3.5	69
312	BONE MINERAL DENSITY IN IRANIAN ADOLESCENTS AND YOUNG ADULTS WITH β^2 -THALASSEMIA MAJOR. Pediatric Hematology and Oncology, 2007, 24, 469-479.	0.8	30
313	Impact of the 3,6,9-Trioxadecyloxy Group on Desazadesferrithiocin Analogue Iron Clearance and Organ Distribution. Journal of Medicinal Chemistry, 2007, 50, 3302-3313.	6.4	14
314	Haemoglobinopathies. Paediatrics and Child Health (United Kingdom), 2007, 17, 311-316.	0.4	3
315	Deferasirox. Drugs, 2007, 67, 2211-2230.	10.9	97
316	Hydrazone chelators for the treatment of iron overload disorders: iron coordination chemistry and biological activity. Dalton Transactions, 2007, , 3232.	3.3	90
317	Case 123: Cardiac Hemosiderosis. Radiology, 2007, 245, 292-295.	7.3	2
318	The Thalassemias and Related Disorders. Baylor University Medical Center Proceedings, 2007, 20, 27-31.	0.5	68
319	The Clinical Guidelines for Myelodysplastic Syndrome. The Korean Journal of Hematology, 2007, 42, 71.	0.7	1
320	Sobrecarga e quelaÃ§Ã£o de ferro na anemia falciforme. Revista Brasileira De Hematologia E Hemoterapia, 2007, 29, .	0.7	11
321	Genetic anemias. , 0, , 316-327.		0
322	R2* imaging of transfusional iron burden at 3T and comparison with 1.5T. Journal of Magnetic Resonance Imaging, 2007, 25, 540-547.	3.4	146
323	Successful management of bleeding with recombinant factor VIIa (NovoSevenÂ®) in a patient with Burkitt lymphoma and thrombosis of the left femoral and left common iliac veins. Pediatric Blood and Cancer, 2007, 49, 332-335.	1.5	8
324	Serum ferritin underestimates liver iron concentration in transfusion independent thalassemia patients as compared to regularly transfused thalassemia and sickle cell patients. Pediatric Blood and Cancer, 2007, 49, 329-332.	1.5	121

#	ARTICLE	IF	CITATIONS
325	Improving clinical outcome in patients with myelodysplastic syndrome and iron overload using iron chelation therapy. <i>Leukemia Research</i> , 2007, 31, S7-S9.	0.8	67
326	Novel treatment options for transfusional iron overload in patients with myelodysplastic syndromes. <i>Leukemia Research</i> , 2007, 31, S16-S22.	0.8	16
327	Allogeneic stem cell transplantation from matched related and unrelated donors in thalassemia major patients using a reduced toxicity fludarabine-based regimen. <i>Bone Marrow Transplantation</i> , 2007, 40, 957-964.	2.4	20
328	A randomised comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease. <i>British Journal of Haematology</i> , 2007, 136, 501-508.	2.5	255
329	Phase Ib clinical trial of starch-conjugated deferoxamine (40SD02): a novel long-acting iron chelator. <i>British Journal of Haematology</i> , 2007, 138, 374-381.	2.5	39
330	Myocardial iron loading by magnetic resonance imaging T2* in good prognostic myelodysplastic syndrome patients on long-term blood transfusions. <i>British Journal of Haematology</i> , 2007, 138, 587-593.	2.5	92
331	Clinical and economic burden of infused iron chelation therapy in the United States. <i>Transfusion</i> , 2007, 47, 1820-1829.	1.6	38
332	Decreased transfusion needs associated with hydroxyurea therapy in Algerian patients with thalassemia major or intermedia. <i>Transfusion</i> , 2007, 47, 1830-1836.	1.6	55
333	The real cost of iron chelation therapy. <i>Transfusion</i> , 2007, 47, 1751-1752.	1.6	2
334	Continuous desferoxamine infusion by an infusor in thalassaemia major. <i>Acta Paediatrica, International Journal of Paediatrics</i> , 2007, 88, 550-552.	1.5	0
335	Neurodevelopmental outcome and haematological course of a long-time survivor with homozygous alpha-thalassaemia: Case report and review of the literature. <i>Acta Paediatrica, International Journal of Paediatrics</i> , 2005, 94, 1330-1333.	1.5	34
336	Chronic zinc toxicity in an infant who received zinc therapy for atopic dermatitis. <i>Acta Paediatrica, International Journal of Paediatrics</i> , 2005, 94, 1333-1335.	1.5	17
337	Relative response of patients with myelodysplastic syndromes and other transfusion-dependent anaemias to deferasirox (ICL670): a 1-yr prospective study. <i>European Journal of Haematology</i> , 2008, 80, 168-176.	2.2	210
338	The heart in transfusion dependent homozygous thalassaemia today – prediction, prevention and management. <i>European Journal of Haematology</i> , 2008, 80, 93-106.	2.2	51
339	La surcharge en fer et ses complications. <i>Journal De Pediatrie Et De Puericulture</i> , 2007, 20, 45-51.	0.0	0
340	Four-year evaluation of myocardial and liver iron assessed prospectively with serial MRI scans in young patients with β -thalassaemia major: comparison between different chelation regimens. <i>European Journal of Haematology</i> , 2007, 78, 52-57.	2.2	29
341	Predictive echo-Doppler indices of left ventricular impairment in B-thalassemic patients. <i>Annals of Hematology</i> , 2007, 86, 429-434.	1.8	21
342	Myocardial and hepatic T2* magnetic resonance evaluation in ex-thalassemic patients after bone-marrow transplantation. <i>International Journal of Cardiovascular Imaging</i> , 2007, 23, 739-745.	1.5	20

#	ARTICLE	IF	CITATIONS
343	Iron overload in patients with myelodysplastic syndromes. <i>Current Hematologic Malignancy Reports</i> , 2007, 2, 13-21.	2.3	6
344	Current status of iron overload and chelation with deferasirox. <i>Indian Journal of Pediatrics</i> , 2007, 74, 759-764.	0.8	23
345	Iron chelation therapy: Clinical effectiveness, economic burden and quality of life in patients with iron overload. <i>Advances in Therapy</i> , 2008, 25, 725-742.	2.9	66
346	Zinc in Thalassemic Patients and Its Relation with Depression. <i>Biological Trace Element Research</i> , 2008, 123, 8-13.	3.5	7
347	A safety, pharmacokinetic and pharmacodynamic investigation of deferasirox (Exjade®; ICL670) in patients with transfusion-dependent anemias and iron-overload: a Phase I study in Japan. <i>International Journal of Hematology</i> , 2008, 88, 73-81.	1.6	40
348	Iron chelation therapy in the myelodysplastic syndromes and aplastic anemia: a review of experience in South Korea. <i>International Journal of Hematology</i> , 2008, 88, 16-23.	1.6	31
349	Body iron metabolism and pathophysiology of iron overload. <i>International Journal of Hematology</i> , 2008, 88, 7-15.	1.6	465
350	Terephthalamide-containing ligands: fast removal of iron from transferrin. <i>Journal of Biological Inorganic Chemistry</i> , 2008, 13, 229-240.	2.6	18
351	Long-term efficacy and safety of deferasirox. <i>Blood Reviews</i> , 2008, 22, S35-S41.	5.7	69
352	Liver biopsy results in patients with sickle cell disease on chronic transfusions: Poor correlation with ferritin levels. <i>Pediatric Blood and Cancer</i> , 2008, 50, 62-65.	1.5	66
353	Transfusional iron burden and liver toxicity after bone marrow transplantation for acute myelogenous leukemia and hemoglobinopathies. <i>Pediatric Blood and Cancer</i> , 2008, 50, 319-324.	1.5	39
354	Magnetic resonance detection of kidney iron deposition in sickle cell disease: A marker of chronic hemolysis. <i>Journal of Magnetic Resonance Imaging</i> , 2008, 28, 698-704.	3.4	73
355	Red blood cell transfusions and iron overload in the treatment of patients with myelodysplastic syndromes. <i>Cancer</i> , 2008, 112, 1089-1095.	4.1	68
356	Outcomes, utilization, and costs among thalassemia and sickle cell disease patients receiving deferoxamine therapy in the United States. <i>American Journal of Hematology</i> , 2008, 83, 263-270.	4.1	41
357	Severe Henoch-Schönlein purpura in a thalassemic patient under deferiprone treatment. <i>American Journal of Hematology</i> , 2008, 83, 165-166.	4.1	11
358	Practical implications of liver and heart iron load assessment by T2* MRI in children and adults with transfusion-dependent anemias. <i>American Journal of Hematology</i> , 2008, 83, 781-783.	4.1	41
359	Kinetics and thermodynamics of complex formation with iron of a new series of dicatecholspermidine siderophore-like ligands. <i>Journal of Inorganic Biochemistry</i> , 2008, 102, 636-646.	3.5	5
360	Synthesis, siderophore activity and iron(III) chelation chemistry of a novel mono-hydroxamate, bis-catecholate siderophore mimic: N ¹ ±, N ¹ µ-Bis[2,3-dihydroxybenzoyl]-l-lysyl-(¹³ -N-methyl-N-hydroxyamido)-l-glutamic acid. <i>Journal of Inorganic Biochemistry</i> , 2008, 102, 850-861.	3.5	12

#	ARTICLE	IF	CITATIONS
361	Traversing the coordination chemistry and chemical biology of hydroxamic acids. <i>Coordination Chemistry Reviews</i> , 2008, 252, 1387-1408.	18.8	235
362	Bilirubin cholelithiasis and haemosiderosis in an anaemic pyruvate kinase-deficient Somali cat. <i>Journal of Small Animal Practice</i> , 2008, 49, 479-482.	1.2	18
363	Quality of life in patients with transfusion-dependent thalassemia after hematopoietic SCT. <i>Bone Marrow Transplantation</i> , 2008, 42, 319-327.	2.4	59
364	Iron overload in hematopoietic cell transplantation. <i>Bone Marrow Transplantation</i> , 2008, 41, 997-1003.	2.4	118
365	Studies in haemoglobin E beta-thalassaemia. <i>British Journal of Haematology</i> , 2008, 141, 388-397.	2.5	103
366	Diagnosing and treating Diamond Blackfan anaemia: results of an international clinical consensus conference. <i>British Journal of Haematology</i> , 2008, 142, 859-876.	2.5	408
367	Hypocalcemia in a Dialysis Patient Treated With Deferasirox for Iron Overload. <i>American Journal of Kidney Diseases</i> , 2008, 52, 587-590.	1.9	30
368	Iron overload detection in rats by means of a susceptometer operating at room temperature. <i>Physics in Medicine and Biology</i> , 2008, 53, 6849-6860.	3.0	6
369	Oral Iron Chelators. <i>Pediatric Clinics of North America</i> , 2008, 55, 461-482.	1.8	20
370	Protective effects of <i>Mangifera indica</i> L extract (Vimang), and its major component mangiferin, on iron-induced oxidative damage to rat serum and liver. <i>Pharmacological Research</i> , 2008, 57, 79-86.	7.1	73
371	Chapter 8 Diamond Blackfan Anemia: A Disorder of Red Blood Cell Development. <i>Current Topics in Developmental Biology</i> , 2008, 82, 217-241.	2.2	58
372	Desferrithiocin Analogues and Nephrotoxicity. <i>Journal of Medicinal Chemistry</i> , 2008, 51, 5993-6004.	6.4	13
373	Cost-utility analysis of deferasirox compared to standard therapy with desferrioxamine for patients requiring iron chelation therapy in the United Kingdom. <i>Current Medical Research and Opinion</i> , 2008, 24, 1609-1621.	1.9	43
374	Structure-Activity Relationships of Novel Iron Chelators for the Treatment of Iron Overload Disease: The Methyl Pyrazinylketone Isonicotinoyl Hydrazone Series. <i>Journal of Medicinal Chemistry</i> , 2008, 51, 331-344.	6.4	91
375	High Prevalence of Iron Overload in Adult Allogeneic Hematopoietic Cell Transplant Survivors. <i>Biology of Blood and Marrow Transplantation</i> , 2008, 14, 790-794.	2.0	65
376	Improved Survival in Patients with Myelodysplastic Syndrome Receiving Iron Chelation Therapy. <i>Clinical Leukemia</i> , 2008, 2, 205-211.	0.2	66
377	Clinical Perspectives on Hereditary Hemochromatosis. <i>Critical Reviews in Clinical Laboratory Sciences</i> , 2008, 45, 451-484.	6.1	22
378	Long-term experience with deferasirox (ICL670), a once-daily oral iron chelator, in the treatment of transfusional iron overload. <i>Expert Opinion on Pharmacotherapy</i> , 2008, 9, 2391-2402.	1.8	40

#	ARTICLE	IF	CITATIONS
379	Design, Synthesis, and Testing of Non-Nephrotoxic Desazadesferrithiocin Polyether Analogues. Journal of Medicinal Chemistry, 2008, 51, 3913-3923.	6.4	18
380	Evaluation of prevalence of drug dependence in beta-thalassemic patients and its risk factors. Journal of Substance Use, 2008, 13, 293-298.	0.7	0
381	Triplex solution for a monogenic problem. Science-Business EXchange, 2008, 1, 794-794.	0.0	0
382	Bloodletting Ameliorates Insulin Sensitivity and Secretion in Parallel to Reducing Liver Iron in Carriers of <i>HFE</i> Gene Mutations. Diabetes Care, 2008, 31, 3-8.	8.6	49
383	Oral Iron Chelators and the Treatment of Iron Overload in Pediatric Patients With Chronic Anemia. Pediatrics, 2008, 121, 1253-1256.	2.1	17
384	Pharmacokinetics, Distribution, Metabolism, and Excretion of Deferasirox and Its Iron Complex in Rats. Drug Metabolism and Disposition, 2008, 36, 2523-2538.	3.3	75
385	Iron overload in myelodysplastic syndromes. Leukemia and Lymphoma, 2008, 49, 427-438.	1.3	37
387	Longitudinal analysis of heart and liver iron in thalassemia major. Blood, 2008, 112, 2973-2978.	1.4	191
389	Management and clinical outcomes of transfusion-dependent thalassaemia major in an Australian tertiary referral clinic. Medical Journal of Australia, 2008, 188, 72-75.	1.7	19
390	The Costs of Drugs Used to Treat Myelodysplastic Syndromes Following National Comprehensive Cancer Network Guidelines. Journal of the National Comprehensive Cancer Network: JNCCN, 2008, 6, 942-953.	4.9	42
391	Mechanisms of and obstacles to iron cardiomyopathy in thalassemia. Frontiers in Bioscience - Landmark, 2008, Volume, 5975.	3.0	8
393	Association between age and serum ferritin level with bone age deficit in children with thalassemia major. Paediatrica Indonesiana, 2008, 48, 33.	0.1	2
394	THE β^2 THALASSEMIAS. , 2009, , 321-322.		0
395	Clinical Aspects of β^2 Thalassemia and Related Disorders. , 2009, , 357-416.		10
396	Understanding Iron Overload. Clinical Journal of Oncology Nursing, 2009, 13, 511-517.	0.6	16
397	Uso da fluorescência de raios X portátil (XRF) in vivo como técnica alternativa para acompanhamento dos níveis de ferro em pacientes com sobrecarga de ferro. Revista Brasileira De Hematologia E Hemoterapia, 2009, 31, 153-159.	0.7	3
398	Effect of Iron-Chelator Deferiprone on the In Vitro Growth of Staphylococci. Journal of Korean Medical Science, 2009, 24, 289.	2.5	27
399	NCCN Task Force: Transfusion and Iron Overload in Patients With Myelodysplastic Syndromes. Journal of the National Comprehensive Cancer Network: JNCCN, 2009, 7, S-1-S-16.	4.9	23

#	ARTICLE	IF	CITATIONS
400	Transfusional Iron Overload. , 0, , 858-869.		4
401	Management of Transfusional Chronic Iron Overload: Focus on Deferasirox. Clinical Medicine Therapeutics, 2009, 1, CMT.S1970.	0.1	1
402	Update on the use of deferasirox in the management of iron overload. Therapeutics and Clinical Risk Management, 2009, 5, 857.	2.0	27
403	The Effects of Deferiprone and Deferasirox on the Structure and Function of β^2 -Thalassemia Hemoglobin. Journal of Biomolecular Structure and Dynamics, 2009, 27, 319-329.	3.5	22
404	Deferasirox (Exjade®) for the Treatment of Iron Overload. Acta Haematologica, 2009, 122, 165-173.	1.4	51
405	Prevention of Cardiomyopathy in Transfusion-Dependent Homozygous Thalassemia Today and the Role of Cardiac Magnetic Resonance Imaging. Advances in Hematology, 2009, 2009, 1-4.	1.0	3
406	Emotional impact in β^2 -thalassaemia major children following cognitive-behavioural family therapy and quality of life of caregiving mothers. Clinical Practice and Epidemiology in Mental Health, 2009, 5, 5.	1.2	57
407	Non-invasive assessment of tissue iron overload. Hematology American Society of Hematology Education Program, 2009, 2009, 215-221.	2.5	67
408	Managing Iron Overload in Patients with Myelodysplastic Syndromes with Oral Deferasirox Therapy. Oncologist, 2009, 14, 489-496.	3.7	17
409	Reduction in labile plasma iron during treatment with deferasirox, a once-daily oral iron chelator, in heavily iron-overloaded patients with β^2 -thalassaemia. European Journal of Haematology, 2009, 82, 454-457.	2.2	70
410	Efficacy and safety of deferasirox, an oral iron chelator, in heavily iron-overloaded patients with β^2 -thalassaemia: the ESCALATOR study. European Journal of Haematology, 2009, 82, 458-465.	2.2	131
411	Absence of cardiac siderosis by MRI T2* despite transfusion burden, hepatic and serum iron overload in Lebanese patients with sickle cell disease. European Journal of Haematology, 2009, 83, 565-571.	2.2	33
412	Exogenous iron increases hemoglobin in β^2 -thalassemic mice. Experimental Hematology, 2009, 37, 172-183.	0.4	34
413	Severe iron overload in Blackfan-Rosenthal anemia: A case-control study. American Journal of Hematology, 2009, 84, 729-732.	4.1	48
414	Improved survival in red blood cell transfusion dependent patients with primary myelofibrosis (PMF) receiving iron chelation therapy. Hematological Oncology, 2010, 28, 40-48.	1.7	30
415	Accurate liver T measurement of iron overload: A simulations investigation and in vivo study. Journal of Magnetic Resonance Imaging, 2009, 30, 313-320.	3.4	46
416	In vitro chelating, cytotoxicity, and blood compatibility of degradable poly(ethylene glycol)-based macromolecular iron chelators. Biomaterials, 2009, 30, 638-648.	11.4	83
417	Iron chelation therapy in the management of thalassemia: the Asian perspectives. International Journal of Hematology, 2009, 90, 435-445.	1.6	61

#	ARTICLE	IF	CITATIONS
419	Double-faced cell-mediated immunity in β^2 -thalassemia major: stimulated phenotype versus suppressed activity. <i>Annals of Hematology</i> , 2009, 88, 21-27.	1.8	45
420	Optimizing iron chelation strategies in β^2 -thalassaemia major. <i>Blood Reviews</i> , 2009, 23, S3-S7.	5.7	59
421	Oral iron chelation and the treatment of iron overload in a pediatric hematology center. <i>Pediatric Blood and Cancer</i> , 2009, 52, 616-620.	1.5	29
422	Efficacy and safety of deferasirox doses of ≥ 30 mg/kg per d in patients with transfusion-dependent anaemia and iron overload. <i>British Journal of Haematology</i> , 2009, 147, 752-759.	2.5	101
423	Iron overload and toxicity: the hidden risk of multiple blood transfusions. <i>Vox Sanguinis</i> , 2009, 97, 185-197.	1.5	153
424	Satisfaction and Adherence in Patients with Iron Overload Receiving Iron Chelation Therapy as Assessed by a Newly Developed Patient Instrument. <i>Value in Health</i> , 2009, 12, 109-117.	0.3	28
425	A Time-Cost Augmented Economic Evaluation of Oral Deferasirox versus Infusional Dereroxmine for Patients with Iron Overload in South Korea. <i>Value in Health</i> , 2009, 12, S78-S81.	0.3	7
426	Combined therapy of silymarin and desferrioxamine in patients with β^2 -thalassemia major: a randomized double-blind clinical trial. <i>Fundamental and Clinical Pharmacology</i> , 2009, 23, 359-365.	1.9	46
427	A mechanistic study of ferrioxamine B reduction by the biological reducing agent ascorbate in the presence of an iron(II) chelator. <i>Inorganica Chimica Acta</i> , 2009, 362, 1787-1792.	2.4	5
428	Iron-overload after autologous hematopoietic cell transplantation. <i>Leukemia Research</i> , 2009, 33, 578-579.	0.8	19
429	The Novel Iron Chelator, 2-Pyridylcarboxaldehyde 2-Thiophenecarboxyl Hydrazone, Reduces Catecholamine-Mediated Myocardial Toxicity. <i>Chemical Research in Toxicology</i> , 2009, 22, 208-217.	3.3	27
430	Cancer cell iron metabolism and the development of potent iron chelators as anti-tumour agents. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 2009, 1790, 702-717.	2.4	214
431	Iron overload following red blood cell transfusion and its impact on disease severity. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 2009, 1790, 694-701.	2.4	114
432	Necrotizing stomatitis: a possible periodontal manifestation of deferiprone-induced agranulocytosis. <i>Oral Surgery Oral Medicine Oral Pathology Oral Radiology and Endodontics</i> , 2009, 108, e13-e19.	1.4	15
433	Thiosemicarbazones from the Old to New: Iron Chelators That Are More Than Just Ribonucleotide Reductase Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2009, 52, 5271-5294.	6.4	338
434	Overview of Iron Chelation Therapy with Desferrioxamine and Deferiprone. <i>Hemoglobin</i> , 2009, 33, S58-S69.	0.8	33
435	Iron overload thalassemic cardiomyopathy: Iron status assessment and mechanisms of mechanical and electrical disturbance due to iron toxicity. <i>Canadian Journal of Cardiology</i> , 2009, 25, 213-218.	1.7	103
436	Diamond-Blackfan Anemia: Diagnosis, Treatment, and Molecular Pathogenesis. <i>Hematology/Oncology Clinics of North America</i> , 2009, 23, 261-282.	2.2	174

#	ARTICLE	IF	CITATIONS
437	Hepatic Iron Overload in Children With Sickle Cell Anemia on Chronic Transfusion Therapy. Journal of Pediatric Hematology/Oncology, 2009, 31, 309-312.	0.6	45
438	Serum ferritin level changes in children with sickle cell disease on chronic blood transfusion are nonlinear and are associated with iron load and liver injury. Blood, 2009, 114, 4632-4638.	1.4	98
439	Pancreatic iron loading predicts cardiac iron loading in thalassemia major. Blood, 2009, 114, 4021-4026.	1.4	137
440	NEW APPROACHES TO THE TREATMENT OF HEMOGLOBINOPATHIES AND THALASSEMIA. , 2009, , 687-688.		0
441	Iron Chelators in Medicinal Applications - Chemical Equilibrium Considerations in Pharmaceutical Activity. Current Medicinal Chemistry, 2009, 16, 2416-2429.	2.4	21
442	Deferasirox for managing transfusional iron overload in people with sickle cell disease. , 2010, , CD007477.		4
443	Retrospective Study on the Combination of Desferrioxamine and Deferasirox for Treatment of Iron-overloaded Thalassemic Patients: First Evidence of More Than 2 Years. Journal of Pediatric Hematology/Oncology, 2010, 32, 400-403.	0.6	28
444	Iron chelation therapy with deferasirox in patients with aplastic anemia: a subgroup analysis of 116 patients from the EPIC trial. Blood, 2010, 116, 2448-2454.	1.4	63
445	Idiosyncratic Drug-Induced Agranulocytosis: The Paradigm of Deferiprone. Hemoglobin, 2010, 34, 291-304.	0.8	30
446	Aluminium and Iron in Humans: Bioaccumulation, Pathology, and Removal. Rejuvenation Research, 2010, 13, 589-598.	1.8	58
447	Conjugates of Desferrioxamine B (DFOB) with Derivatives of Adamantane or with Orally Available Chelators as Potential Agents for Treating Iron Overload. Journal of Medicinal Chemistry, 2010, 53, 1370-1382.	6.4	44
448	Long-term response to deferiprone therapy in Asian Indians. Annals of Hematology, 2010, 89, 135-140.	1.8	6
449	An instrument assessing satisfaction with iron chelation therapy: Psychometric testing from an open-label clinical trial. Advances in Therapy, 2010, 27, 533-546.	2.9	11
450	Deferasirox: Oral, once daily iron chelator "an expert opinion. Indian Journal of Pediatrics, 2010, 77, 185-191.	0.8	18
451	The Xmn1 polymorphic site 5' to the G13 gene and its correlation to the G13:A13 ratio, age at first blood transfusion and clinical features in β^2 -Thalassemia patients from Western Iran. Molecular Biology Reports, 2010, 37, 159-164.	2.3	36
452	Distribution of cardiac iron measured by magnetic resonance imaging (MRI). Journal of Magnetic Resonance Imaging, 2010, 32, 1104-1109.	3.4	6
453	Separate MRI quantification of dispersed (ferritin-like) and aggregated (hemosiderin-like) storage iron. Magnetic Resonance in Medicine, 2010, 63, 1201-1209.	3.0	40
454	The iron complex of Dp44mT is redox-active and induces hydroxyl radical formation: An EPR study. Journal of Inorganic Biochemistry, 2010, 104, 1224-1228.	3.5	59

#	ARTICLE	IF	CITATIONS
455	Deferasirox in iron-overloaded patients with transfusion-dependent myelodysplastic syndromes: Results from the large 1-year EPIC study. <i>Leukemia Research</i> , 2010, 34, 1143-1150.	0.8	164
456	Prospective assessment of effects on iron-overload parameters of deferasirox therapy in patients with myelodysplastic syndromes. <i>Leukemia Research</i> , 2010, 34, 1560-1565.	0.8	44
457	Delineating parameters of iron overload in MDS patients treated with deferasirox. <i>Leukemia Research</i> , 2010, 34, 1556-1557.	0.8	1
458	Assessment of cardiac iron by MRI susceptometry and R2* in patients with thalassemia. <i>Magnetic Resonance Imaging</i> , 2010, 28, 363-371.	1.8	17
459	Pathophysiology and management of inherited bone marrow failure syndromes. <i>Blood Reviews</i> , 2010, 24, 101-122.	5.7	432
460	Synthesis and biological properties of iron chelators based on a bis-2-(2-hydroxy-phenyl)-thiazole-4-carboxamide or -thiocarboxamide (BHPTC) scaffold. <i>Bioorganic and Medicinal Chemistry</i> , 2010, 18, 689-695.	3.0	13
461	Clinical consequences of iron overload from chronic red blood cell transfusions, its diagnosis, and its management by chelation therapy. <i>Transfusion</i> , 2010, 50, 1144-1155.	1.6	57
462	Current therapeutic approaches for patients with myelodysplastic syndromes. <i>British Journal of Haematology</i> , 2010, 150, 131-143.	2.5	29
463	Combined iron chelation therapy. <i>Annals of the New York Academy of Sciences</i> , 2010, 1202, 79-86.	3.8	57
464	Evaluation of angiogenesis with vascular endothelial growth factor in patients with thalassemia major. <i>Pediatrics International</i> , 2010, 52, 247-251.	0.5	6
465	Observational study of iron overload as assessed by magnetic resonance imaging in an adult population of transfusion-dependent patients with β^2 thalassaemia: significant association between low cardiac T2* < 10 ms and cardiac events. <i>Internal Medicine Journal</i> , 2010, 40, 419-426.	0.8	23
466	Hereditary sideroblastic anemias. , 0, , 260-273.		0
467	Efficacy and safety of deferiprone (Ferriprox), an oral iron-chelating agent, in pediatric patients. <i>The Korean Journal of Hematology</i> , 2010, 45, 58.	0.7	8
468	Red Blood Cell Transfusion Independence Following the Initiation of Iron Chelation Therapy in Myelodysplastic Syndrome. <i>Advances in Hematology</i> , 2010, 2010, 1-5.	1.0	41
469	Iron Overload in Sickle Cell Disease. <i>Advances in Hematology</i> , 2010, 2010, 1-9.	1.0	52
470	Improved Treatment Satisfaction and Convenience with Deferasirox in Iron-Overloaded Patients with β^2 -Thalassemia: Results from the ESCALATOR Trial. <i>Acta Haematologica</i> , 2010, 123, 220-225.	1.4	43
472	Protein C levels in β^2 -thalassemia major patients in the east Nile delta of Egypt. <i>Hematology/ Oncology and Stem Cell Therapy</i> , 2010, 3, 60-65.	0.9	17
474	Modulation of inflammatory response after spinal cord trauma with deferoxamine, an iron chelator. <i>Free Radical Research</i> , 2010, 44, 694-709.	3.3	22

#	ARTICLE	IF	CITATIONS
475	Oral Iron Chelators. Hematology/Oncology Clinics of North America, 2010, 24, 229-248.	2.2	13
476	Hematopoietic Stem Cell Transplantation for Hemoglobinopathies: Current Practice and Emerging Trends. Pediatric Clinics of North America, 2010, 57, 181-205.	1.8	28
478	The Impact of Polyether Chain Length on the Iron Clearing Efficiency and Physiochemical Properties of Desferrithiocin Analogues. Journal of Medicinal Chemistry, 2010, 53, 2843-2853.	6.4	10
480	Iron Overload in Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation: Quantification of Iron Burden by a Superconducting Quantum Interference Device (SQUID) and Therapeutic Effectiveness of Phlebotomy. Biology of Blood and Marrow Transplantation, 2010, 16, 115-122.	2.0	57
481	Increased survival and reversion of iron-induced cardiac disease in patients with thalassemia major receiving intensive combined chelation therapy as compared to desferoxamine alone. Blood Cells, Molecules, and Diseases, 2010, 45, 136-139.	1.4	45
482	Cord blood transplantation in patients with hemoglobinopathies. Transfusion and Apheresis Science, 2010, 42, 277-281.	1.0	18
483	Nanoparticle and Iron Chelators as a Potential Novel Alzheimer Therapy. Methods in Molecular Biology, 2010, 610, 123-144.	0.9	87
484	Chronic Myeloid Neoplasias and Clonal Overlap Syndromes. , 2010, , .		1
485	Deferasirox for managing iron overload in people with myelodysplastic syndrome. , 2010, , CD007461.		4
486	HbE/ β^2 -Thalassemia: Basis of Marked Clinical Diversity. Hematology/Oncology Clinics of North America, 2010, 24, 1055-1070.	2.2	34
487	Which Psychosocial Factors are Related to Chelation Adherence in Thalassemia? A Systematic Review. Hemoglobin, 2010, 34, 305-321.	0.8	20
488	Comparison of Clinically Used and Experimental Iron Chelators for Protection against Oxidative Stress-Induced Cellular Injury. Chemical Research in Toxicology, 2010, 23, 1105-1114.	3.3	61
489	Chelators to the Rescue: Different Horses for Different Courses!. Chemical Research in Toxicology, 2011, 24, 279-282.	3.3	8
490	Diabetes and chronic oxidative stress. A perspective based on the possible usefulness of ozone therapy. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2011, 5, 45-49.	3.6	35
491	Complications of β^2 -Thalassemia Intermedia in Iran During 1996-2010 (Single-Center Study). Pediatric Hematology and Oncology, 2011, 28, 497-508.	0.8	15
492	Transfusion and Chelation Practices in Sickle Cell Disease: A Regional Perspective. Pediatric Hematology and Oncology, 2011, 28, 124-133.	0.8	20
493	Optimizing Therapy for Iron Overload in the Myelodysplastic Syndromes. Drugs, 2011, 71, 155-177.	10.9	18
494	Iron-Chelating Therapies in a Transfusion-Dependent Thalassemia Population in Thailand. Clinical Drug Investigation, 2011, 31, 493-505.	2.2	25

#	ARTICLE	IF	CITATIONS
495	Iron-Chelating Therapy for Transfusional Iron Overload. <i>New England Journal of Medicine</i> , 2011, 364, 146-156.	27.0	301
496	Improvement in Liver Pathology of Patients With β^2 -Thalassemia Treated With Deferasirox for at Least 3 Years. <i>Gastroenterology</i> , 2011, 141, 1202-1211.e3.	1.3	73
497	β^2 -thalassemia: a model for elucidating the dynamic regulation of ineffective erythropoiesis and iron metabolism. <i>Blood</i> , 2011, 118, 4321-4330.	1.4	168
498	Iron overload and allogeneic hematopoietic stem-cell transplantation. <i>Expert Review of Hematology</i> , 2011, 4, 71-80.	2.2	20
499	Iron Overload in Patients with Acute Leukemia or MDS Undergoing Myeloablative Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, 852-860.	2.0	98
500	Thalassemia intermedia is associated with a proatherogenic biochemical phenotype. <i>Blood Cells, Molecules, and Diseases</i> , 2011, 46, 294-299.	1.4	11
501	High frequency of autoimmunization among transfusion-dependent Tunisian thalassaemia patients. <i>Transfusion and Apheresis Science</i> , 2011, 45, 199-202.	1.0	25
502	Role of metal dyshomeostasis in Alzheimer's disease. <i>Metallomics</i> , 2011, 3, 267.	2.4	267
503	Myelodysplastic Syndromes. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2011, 9, 30-56.	4.9	177
504	Sobrecarga de ferro transfusional em portadores de anemia falciforme: compara��o entre resson��ncia magn��tica e ferritina s��rica. <i>Radiologia Brasileira</i> , 2011, 44, 151-155.	0.7	0
505	Thalassemia Syndrome. , 2011, , .		1
506	Myocardial Iron Loading in Patients With Thalassemia Major in Turkey and the Potential Role of Splenectomy in Myocardial Siderosis. <i>Journal of Pediatric Hematology/Oncology</i> , 2011, 33, 374-378.	0.6	26
507	Comparing the potential renal protective activity of desferrioxamine B and the novel chelator desferrioxamine B- <i>N</i> -(3-hydroxyadamant-1-yl)carboxamide in a cell model of myoglobinuria. <i>Biochemical Journal</i> , 2011, 435, 669-677.	3.7	15
508	Use of deferiprone for iron chelation in patients with transfusion��dependent thalassaemia. <i>Journal of Paediatrics and Child Health</i> , 2011, 47, 812-817.	0.8	13
509	Australian guidelines for the assessment of iron overload and iron chelation in transfusion��dependent thalassaemia major, sickle cell disease and other congenital anaemias. <i>Internal Medicine Journal</i> , 2011, 41, 516-524.	0.8	45
510	Quantitative computed tomography assessment of transfusional iron overload. <i>British Journal of Haematology</i> , 2011, 153, 780-785.	2.5	21
511	Iron overload is associated with low anti-m��llerian hormone in women with transfusion-dependent β^2 -thalassaemia. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2011, 118, 825-831.	2.3	24
512	Response of iron overload to deferasirox in rare transfusion��dependent anaemias: equivalent effects on serum ferritin and labile plasma iron for haemolytic or production anaemias. <i>European Journal of Haematology</i> , 2011, 87, 338-348.	2.2	28

#	ARTICLE	IF	CITATIONS
513	Achieving treatment goals of reducing or maintaining body iron burden with deferasirox in patients with β^2 -thalassaemia: results from the ESCALATOR study. <i>European Journal of Haematology</i> , 2011, 87, 349-354.	2.2	12
514	Comparison of various iron chelators used in clinical practice as protecting agents against catecholamine-induced oxidative injury and cardiotoxicity. <i>Toxicology</i> , 2011, 289, 122-131.	4.2	35
515	Maternal quercetin intake during pregnancy results in an adapted iron homeostasis at adulthood. <i>Toxicology</i> , 2011, 290, 350-358.	4.2	44
516	Iron chelation with salicylaldehyde isonicotinoyl hydrazone protects against catecholamine autoxidation and cardiotoxicity. <i>Free Radical Biology and Medicine</i> , 2011, 50, 537-549.	2.9	42
517	Synthesis and Initial <i>in Vitro</i> Evaluations of Novel Antioxidant Aroylhydrazone Iron Chelators with Increased Stability against Plasma Hydrolysis. <i>Chemical Research in Toxicology</i> , 2011, 24, 290-302.	3.3	52
518	Desferrithiocin analogue iron chelators: iron clearing efficiency, tissue distribution, and renal toxicity. <i>BioMetals</i> , 2011, 24, 239-258.	4.1	26
519	Iron status and treatment modalities in transfusion-dependent patients with myelodysplastic syndromes. <i>Annals of Hematology</i> , 2011, 90, 655-666.	1.8	12
520	Limitations of using logarithmic transformation and linear fitting to estimate relaxation rates in iron-loaded liver. <i>Pediatric Radiology</i> , 2011, 41, 1259-1265.	2.0	17
521	Water-quality issues in the Niger Delta of Nigeria: a look at heavy metal levels and some physicochemical properties. <i>Environmental Science and Pollution Research</i> , 2011, 18, 237-246.	5.3	56
522	Reversible Fanconi syndrome in a pediatric patient on deferasirox. <i>Pediatric Blood and Cancer</i> , 2011, 56, 674-676.	1.5	48
523	Insidious iron burden in pediatric patients with acute lymphoblastic leukemia. <i>Pediatric Blood and Cancer</i> , 2011, 56, 368-371.	1.5	30
524	Reduced transverse relaxation rate (RR2) for improved sensitivity in monitoring myocardial iron in thalassemia. <i>Journal of Magnetic Resonance Imaging</i> , 2011, 33, 1510-1516.	3.4	7
525	Controversies surrounding iron chelation therapy for MDS. <i>Blood Reviews</i> , 2011, 25, 17-31.	5.7	40
526	Enhancing the selectivity of an iron binding hydrogel. <i>European Polymer Journal</i> , 2011, 47, 1485-1488.	5.4	6
527	In vitro analysis of iron chelating activity of flavonoids. <i>Journal of Inorganic Biochemistry</i> , 2011, 105, 693-701.	3.5	195
528	Synthesis of gemini triethylene-tetramine bridged bis-tridentate iron(III) chelators. <i>Tetrahedron</i> , 2011, 67, 2149-2154.	1.9	0
529	The Potent and Novel Thiosemicarbazone Chelators Di-2-pyridylketone-4,4-dimethyl-3-thiosemicarbazone and 2-Benzoylpyridine-4,4-dimethyl-3-thiosemicarbazone Affect Crucial Thiol Systems Required for Ribonucleotide Reductase Activity. <i>Molecular Pharmacology</i> , 2011, 79, 921-931.	2.3	44
530	Pharmacological Induction of Neuroglobin Expression. <i>Pharmacology</i> , 2011, 87, 81-84.	2.2	35

#	ARTICLE	IF	CITATIONS
531	Elevated liver iron concentration is a marker of increased morbidity in patients with α thalassemia intermedia. Haematologica, 2011, 96, 1605-1612.	3.5	153
532	Continued improvement in myocardial T2* over two years of deferasirox therapy in α -thalassemia major patients with cardiac iron overload. Haematologica, 2011, 96, 48-54.	3.5	70
533	Serum Iron Markers Are Inadequate for Guiding Iron Repletion in Chronic Kidney Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2011, 6, 77-83.	4.5	119
534	Safety and efficacy of deferasirox in multitransfused Indian children with α -thalassaemia major. Annals of Tropical Paediatrics, 2011, 31, 47-51.	1.0	13
535	Desferrioxamine-related ocular toxicity: A case report. Indian Journal of Ophthalmology, 2012, 60, 315.	1.1	33
536	Chelators in the Treatment of Iron Accumulation in Parkinson's Disease. International Journal of Cell Biology, 2012, 2012, 1-12.	2.5	62
537	Evaluation of QT interval in β^2 thalassemia major patients in comparison with control group. Heart Views, 2012, 13, 42.	0.2	3
538	Iron Chelators for the Treatment of Cancer. Current Medicinal Chemistry, 2012, 19, 2689-2702.	2.4	158
539	Relationship between Plasma Ferritin Level and Siderocyte Number in Splenectomized β^2 -Thalassemia/HbE Patients. Anemia, 2012, 2012, 1-4.	1.7	3
540	A prospective study for prevalence and/or development of transfusion-transmitted infections in multiply transfused thalassemia major patients. Asian Journal of Transfusion Science, 2012, 6, 151.	0.3	20
541	The effect of combined therapy with deferoxamine and deferiprone on serum ferritin level of beta-thalassemic patients. Hematology, 2012, 17, 183-186.	1.5	12
542	Cardiovascular Aspect of Beta-Thalassaemia. Cardiovascular and Hematological Agents in Medicinal Chemistry, 2012, 10, 25-30.	1.0	17
543	Chelation use and iron burden in North American and British thalassemia patients: a report from the Thalassemia Longitudinal Cohort. Blood, 2012, 119, 2746-2753.	1.4	78
544	Iron out for nontransfused thalassemia. Blood, 2012, 120, 928-929.	1.4	0
545	Spin density projection-assisted R2 magnetic resonance imaging of the liver in the management of body iron stores in patients receiving multiple red blood cell transfusions: an audit and retrospective study in South Australia. Internal Medicine Journal, 2012, 42, 990-996.	0.8	2
546	MRI-Based Liver Iron Content Predicts for Nonrelapse Mortality in MDS and AML Patients Undergoing Allogeneic Stem Cell Transplantation. Clinical Cancer Research, 2012, 18, 6460-6468.	7.0	66
547	MRI of cardiac iron overload. Journal of Magnetic Resonance Imaging, 2012, 36, 1052-1059.	3.4	37
548	Magnetic resonance imaging in the evaluation of iron overload: a comparison of MRI, echocardiography and serum ferritin level in patients with β^2 -thalassemia major. Clinical Imaging, 2012, 36, 483-488.	1.5	19

#	ARTICLE	IF	CITATIONS
549	Lifetime Cost-Utility Analyses of Deferasirox in Beta-Thalassaemia Patients with Chronic Iron Overload. <i>Clinical Drug Investigation</i> , 2012, 32, 805-815.	2.2	15
550	Deferasirox for managing iron overload in people with thalassaemia. , 2012, , CD007476.		25
551	Substituent Effects on Desferrithiocin and Desferrithiocin Analogue Iron-Clearing and Toxicity Profiles. <i>Journal of Medicinal Chemistry</i> , 2012, 55, 7090-7103.	6.4	10
552	A semiautomatic postprocessing of liver R2* measurement for assessment of liver iron overload. <i>Magnetic Resonance Imaging</i> , 2012, 30, 799-806.	1.8	12
553	Ischemia modified albumin: An oxidative stress marker in β^2 -thalassemia major. <i>Clinica Chimica Acta</i> , 2012, 413, 907-910.	1.1	31
554	Effects of phlebotomy-induced reduction of body iron stores on metabolic syndrome: results from a randomized clinical trial. <i>BMC Medicine</i> , 2012, 10, 54.	5.5	127
555	Iron chelation therapy in patients with transfusionâ€dependent myelodysplastic syndrome. <i>Transfusion</i> , 2012, 52, 2078-2080.	1.6	3
556	Gastrointestinal, Hepatobiliary, Pancreatic, and Iron-Related Diseases in Long-Term Survivors of Allogeneic Hematopoietic Cell Transplantation. <i>Seminars in Hematology</i> , 2012, 49, 43-58.	3.4	29
557	Iron overload and toxicity: implications for anesthesiologists. <i>Journal of Clinical Anesthesia</i> , 2012, 24, 419-425.	1.6	19
558	Improved survival with iron chelation therapy for red blood cell transfusion dependent lower IPSS risk MDS may be more significant in patients with a non-RARS diagnosis. <i>Leukemia Research</i> , 2012, 36, 1380-1386.	0.8	35
559	Beyond the Definitions of the Phenotypic Complications of Sick Cell Disease: An Update on Management. <i>Scientific World Journal</i> , The, 2012, 2012, 1-55.	2.1	125
560	Nanoparticle Delivery of Transition-Metal Chelators to the Brain: Oxidative Stress will Never See it Coming!. <i>CNS and Neurological Disorders - Drug Targets</i> , 2012, 11, 81-85.	1.4	35
561	Bp44mT: an orally active iron chelator of the thiosemicarbazone class with potent antiâ€tumour efficacy. <i>British Journal of Pharmacology</i> , 2012, 165, 148-166.	5.4	90
562	Antiproliferative and iron chelating efficiency of the new bis-8-hydroxyquinoline benzylamine chelator S1 in hepatocyte cultures. <i>Chemico-Biological Interactions</i> , 2012, 195, 165-172.	4.0	20
563	Persistence and compliance of deferoxamine versus deferasirox in Medicaid patients with sickle-cell disease. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2012, 37, 173-181.	1.5	25
564	Iron chelation therapy in the management of transfusionâ€related cardiac iron overload. <i>Transfusion</i> , 2012, 52, 2256-2268.	1.6	14
565	Deferasirox treatment of ironâ€overloaded chelationâ€naïve and prechelated patients with myelodysplastic syndromes in medical practice: results from the observational studies eXtend and eXjange. <i>European Journal of Haematology</i> , 2012, 88, 260-268.	2.2	36
566	Renal aspects of thalassaemia a changing paradigm. <i>European Journal of Haematology</i> , 2012, 89, 187-197.	2.2	42

#	ARTICLE	IF	CITATIONS
567	Relative efficacy of steroid therapy in immune thrombocytopenia mediated by antiplatelet GPIIb/IIIa versus GPIb-IX antibodies. American Journal of Hematology, 2012, 87, 206-208.	4.1	85
568	Treatment of molecular relapse in patients with acute myeloid leukemia using clofarabine monotherapy. American Journal of Hematology, 2012, 87, 211-213.	4.1	3
569	The potential role of pretransplant HBcIgG seropositivity as predictor of clinically relevant cytomegalovirus infection in patients with lymphoma undergoing autologous hematopoietic stem cell transplantation: A study from the Rome Transplant Network. American Journal of Hematology, 2012, 87, 213-217.	4.1	14
570	TP53 mutations and polymorphisms in primary myelofibrosis. American Journal of Hematology, 2012, 87, 204-206.	4.1	14
571	Practical approach for characterization of glucose 6-phosphate dehydrogenase (G6PD) deficiency in countries with population ethnically heterogeneous: Description of seven new G6PD mutants. American Journal of Hematology, 2012, 87, 208-210.	4.1	7
572	Fetal hemoglobin in sickle cell anemia: Molecular characterization of the unusually high fetal hemoglobin phenotype in African Americans. American Journal of Hematology, 2012, 87, 217-219.	4.1	30
573	Spontaneous graft versus host disease occurring in a patient with multiple myeloma after autologous stem cell transplant. American Journal of Hematology, 2012, 87, 219-221.	4.1	23
574	Transfusional iron overload in children with sickle cell anemia on chronic transfusion therapy for secondary stroke prevention. American Journal of Hematology, 2012, 87, 221-223.	4.1	21
575	Complications of implantable venous access devices in patients with sickle cell disease. American Journal of Hematology, 2012, 87, 224-226.	4.1	24
576	Inhibition of cell-mediated immunity by the histone deacetylase inhibitor vorinostat: Implications for therapy of cutaneous T-cell lymphoma. American Journal of Hematology, 2012, 87, 226-228.	4.1	9
577	Safety of plasma-derived protein C for treating disseminated intravascular coagulation in adult patients with active cancer. American Journal of Hematology, 2012, 87, 230-232.	4.1	2
578	The diagnostic value of biopsy of small peripheral lymph nodes in patients with suspected lymphoma. American Journal of Hematology, 2012, 87, 228-230.	4.1	2
579	Blood tests may predict early primary myelofibrosis in patients presenting with essential thrombocythemia. American Journal of Hematology, 2012, 87, 203-204.	4.1	29
580	Deferoxamine-induced dysplasia-like skeletal abnormalities at radiography and MRI. Pediatric Radiology, 2013, 43, 1159-1165.	2.0	7
581	Treating iron overload in patients with nontransfusion-dependent thalassemia. American Journal of Hematology, 2013, 88, 409-415.	4.1	67
582	Non-Hfe Iron Overload: Is Phlebotomy the Answer?. Current Hepatitis Reports, 2013, 12, 20-27.	0.3	1
583	The management of iron overload in allogeneic hematopoietic stem cell transplant (alloHSCT) recipients: Where do we stand?. Annals of Hematology, 2013, 92, 577-586.	1.8	24
584	Efficacy and safety of deferasirox at low and high iron burdens: results from the EPIC magnetic resonance imaging substudy. Annals of Hematology, 2013, 92, 211-219.	1.8	35

#	ARTICLE	IF	CITATIONS
585	Synthesis and biological evaluation of substituted 2-benzoylpyridine thiosemicarbazones: Novel structure-activity relationships underpinning their anti-proliferative and chelation efficacy. Bioorganic and Medicinal Chemistry Letters, 2013, 23, 967-974.	2.2	35
586	Oral deferiprone for iron chelation in people with thalassaemia. The Cochrane Library, 2013, , CD004839.	2.8	37
587	Chelation Therapy. , 2013, , 987-1013.		2
588	Association of iron overload with allogeneic hematopoietic cell transplantation outcomes: a prospective cohort study using R2-MRI-measured liver iron content. Blood, 2013, 122, 1678-1684.	1.4	66
590	Regional consensus opinion for the management of Beta thalassemia major in the Arabian Gulf area. Orphanet Journal of Rare Diseases, 2013, 8, 143.	2.7	16
591	Desferrioxamine mesylate for managing transfusional iron overload in people with transfusion-dependent thalassaemia. The Cochrane Library, 2013, , CD004450.	2.8	47
592	Novel Chelators for Cancer Treatment: Where Are We Now?. Antioxidants and Redox Signaling, 2013, 18, 973-1006.	5.4	160
593	The oral iron chelator deferasirox might improve survival in allogeneic hematopoietic cell transplant (alloH SCT) recipients with transfusional iron overload. Transfusion and Apheresis Science, 2013, 49, 295-301.	1.0	30
594	The use of exogenous iron by professional cyclists pervades abdominal organs but not the heart. International Journal of Cardiology, 2013, 167, 2341-2343.	1.7	9
595	Three most common nonsynonymous UGT1A6*2 polymorphisms (Thr181Ala, Arg184Ser and Ser7Ala) and therapeutic response to deferiprone in β^2 -thalassemia major patients. Gene, 2013, 531, 301-305.	2.2	10
596	Management of the Thalassemias. Cold Spring Harbor Perspectives in Medicine, 2013, 3, a011767-a011767.	6.2	30
597	Hematological improvement during iron-chelation therapy in myelodysplastic syndromes: The experience of the "Rete Ematologica Lombarda". Leukemia Research, 2013, 37, 1233-1240.	0.8	20
598	Questioning the validity of a recent randomized trial on paricalcitol in patients with echocardiographic evidence of cardiac hypertrophy. International Journal of Cardiology, 2013, 167, 2343-2344.	1.7	1
599	A pharmaco-economic evaluation of deferasirox for treating patients with iron overload caused by transfusion-dependent thalassemia in Taiwan. Journal of the Formosan Medical Association, 2013, 112, 221-229.	1.7	10
600	Different approaches to the study of chelating agents for iron and aluminium overload pathologies. Analytical and Bioanalytical Chemistry, 2013, 405, 585-601.	3.7	29
601	Pharmacology of Iron Transport. Annual Review of Pharmacology and Toxicology, 2013, 53, 17-36.	9.4	28
602	Morbidities and Mortality in Transfusion-Dependent Beta-Thalassemia Patients (Single-Center) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 102	0.8	35
603	Assessment and management of iron overload in β^2 -thalassaemia major patients during the 21st century: a real-life experience from the <sc>W</sc>ebthal project. British Journal of Haematology, 2013, 161, 872-883.	2.5	31

#	ARTICLE	IF	CITATIONS
604	Iron Chelation in the Treatment of Cancer: A New Role for Deferasirox?. Journal of Clinical Pharmacology, 2013, 53, 885-891.	2.0	70
605	The Iron Chelator, Deferasirox, as a Novel Strategy for Cancer Treatment: Oral Activity Against Human Lung Tumor Xenografts and Molecular Mechanism of Action. Molecular Pharmacology, 2013, 83, 179-190.	2.3	106
606	Design of Long Circulating Nontoxic Dendritic Polymers for the Removal of Iron <i>in Vivo</i>. ACS Nano, 2013, 7, 10704-10716.	14.6	70
607	Growth and endocrine disorders in thalassemia: The international network on endocrine complications in thalassemia (I-CET) position statement and guidelines. Indian Journal of Endocrinology and Metabolism, 2013, 17, 8.	0.4	105
608	Common Complications in Beta-Thalassemia Patients.. UHOD - Uluslararası Hematoloji-Onkoloji Dergisi, 2013, 23, 193-199.	0.1	10
609	Salvia miltiorrhiza (Danshen) Injection Ameliorates Iron Overload-Induced Cardiac Damage in Mice. Planta Medica, 2013, 79, 744-752.	1.3	34
610	Thalassaemia major and the heart: a toxic cardiomyopathy tamed?. Heart, 2013, 99, 827-834.	2.9	14
611	Prooxidant Mechanisms in Iron Overload Cardiomyopathy. BioMed Research International, 2013, 2013, 1-8.	1.9	46
612	Prognostic impact of pretransplant iron overload measured with magnetic resonance imaging on severe infections in allogeneic stem cell transplantation. European Journal of Haematology, 2013, 91, 85-93.	2.2	13
613	Pain over time and its effects on life in thalassemia. American Journal of Hematology, 2013, 88, 939-943.	4.1	19
614	Liver iron quantification by 3 tesla MRI: Calibration on a rabbit model. Journal of Magnetic Resonance Imaging, 2013, 38, 1585-1590.	3.4	9
615	Deferiprone (GPOâ€”ONE [®]) monotherapy reduces iron overload in transfusionâ€”dependent thalassemias: 1â€”year results from a multicenter prospective, single arm, open label, dose escalating phase III pediatric study (GPOâ€”ONE; A001) from Thailand. American Journal of Hematology, 2013, 88, 251-260.	4.1	43
616	Thromboxane A ₂ Mediates Iron-Overload Cardiomyopathy in Mice Through Calcineurin-Nuclear Factor of Activated T Cells Signaling Pathway. Circulation Journal, 2013, 77, 2586-2595.	1.6	23
617	Ferritin and FerriScan in HCT recipients. Blood, 2013, 122, 1539-1541.	1.4	1
618	Magnetic susceptibility as a <i>B</i> ₀ field strength independent MRI biomarker of liver iron overload. Magnetic Resonance in Medicine, 2013, 70, 648-656.	3.0	36
619	Use of Portable X-ray Fluorescence (PXRF) In Vivo as an Alternative Technique for the Assessment of Iron Levels in Patients With Thalassemia and Hemochromatosis. Health Physics, 2013, 104, 132-138.	0.5	14
620	Deferasirox, an oral chelator in the treatment of iron overload. Italian Journal of Medicine, 2013, 1, 35.	0.3	0
621	Pharmacogenetic Study of Deferasirox, an Iron Chelating Agent. PLoS ONE, 2013, 8, e64114.	2.5	23

#	ARTICLE	IF	CITATION
622	Ineffective Erythropoiesis in β -Thalassemia. Scientific World Journal, The, 2013, 2013, 1-11.	2.1	92
623	Quality of life among Iranian patients with beta-thalassemia major using the SF-36 questionnaire. Sao Paulo Medical Journal, 2013, 131, 166-172.	0.9	33
624	Korean Guideline for Iron Chelation Therapy in Transfusion-Induced Iron Overload. Journal of Korean Medical Science, 2013, 28, 1563.	2.5	10
625	Quantitative Analysis of the Anti-Proliferative Activity of Combinations of Selected Iron-Chelating Agents and Clinically Used Anti-Neoplastic Drugs. PLoS ONE, 2014, 9, e88754.	2.5	23
626	Clinical outcomes of transfusion-associated iron overload in patients with refractory chronic anemia. Patient Preference and Adherence, 2014, 8, 513.	1.8	12
627	Levels of Calcium, Corrected Calcium, Alkaline Phosphatase and Inorganic Phosphorus in Patients' Serum with β -Thalassemia Major on Subcutaneous Deferoxamine. Journal of Hematology & Thromboembolic Diseases, 2014, 02, .	0.1	7
628	Antioxidants as Complementary Medication in Thalassemia. , 0, , .		1
629	Deferasirox for managing transfusional iron overload in people with sickle cell disease. The Cochrane Library, 2017, 2017, CD007477.	2.8	7
630	Diethylentriaminepenta acetic acid glucose conjugates as a cell permeable iron chelator. Journal of Pharmacology and Pharmacotherapeutics, 2014, 5, 27-32.	0.4	6
631	Survey of HFE Gene C282Y Mutation in Turkish Beta-Thalassemia Patients and Healthy Population: A Preliminary Study. Turkish Journal of Haematology, 2014, 31, 272-275.	0.5	2
632	MHealth application: Mobile thalassemia patient management application. , 2014, , .		3
633	Compliance and satisfaction with deferiasirox (Exjade [®]) compared with deferoxamine in patients with transfusion-dependent beta-thalassemia. Hematology, 2014, 19, 187-191.	1.5	24
634	DOSE TITRATION OF DEFERASIROX IRON CHELATION THERAPY BY MAGNETIC RESONANCE IMAGING FOR CHRONIC IRON STORAGE DISEASE IN THREE ADULT RED BALD-HEADED UAKARI (CACAJAO CALVUS) Tj ETQq0 0 0 r gBT /Overlock 10 T	0.5	1
635	A novel semiautomatic parenchyma extraction method for improved MRI R2* relaxometry of iron loaded liver. Journal of Magnetic Resonance Imaging, 2014, 40, 67-78.	3.4	7
636	Fat and Iron Quantification in the Liver. Topics in Magnetic Resonance Imaging, 2014, 23, 73-94.	1.2	43
637	Cardiac Involvement in Hemochromatosis. Cardiology in Review, 2014, 22, 56-68.	1.4	101
638	Iron chelation. Current Opinion in Hematology, 2014, 21, 179-185.	2.5	55
639	Iron overload and chelation therapy in myelodysplastic syndromes. Critical Reviews in Oncology/Hematology, 2014, 91, 64-73.	4.4	46

#	ARTICLE	IF	CITATIONS
640	Deferoxamine promotes osteoblastic differentiation in human periodontal ligament cells via the nuclear factor erythroid 2-related factor-mediated antioxidant signaling pathway. Journal of Periodontal Research, 2014, 49, 563-573.	2.7	38
641	Hematopoietic Cell Transplantation in Children with Cancer. Pediatric Oncology, 2014, , .	0.5	3
642	R2* as a surrogate measure of ferriscan iron quantification in thalassemia. Journal of Magnetic Resonance Imaging, 2014, 39, 1007-1011.	3.4	16
643	Multicenter validation of spin-density projection-assisted R2-MRI for the noninvasive measurement of liver iron concentration. Magnetic Resonance in Medicine, 2014, 71, 2215-2223.	3.0	100
644	Cell Penetrating Peptide (CPP)-Conjugated Desferrioxamine for Enhanced Neuroprotection: Synthesis and in Vitro Evaluation. Bioconjugate Chemistry, 2014, 25, 2067-2080.	3.6	19
645	Comparison of Tissue Doppler Imaging with MRI T2* and 24-Hour Rhythm Holter Heart Rate Variability for Diagnosing Early Cardiac Impairment in Thalassemia Major Patients. Pediatric Hematology and Oncology, 2014, 31, 597-606.	0.8	5
646	Siderophore-drug complexes: potential medicinal applications of the "Trojan horse" strategy. Trends in Pharmacological Sciences, 2014, 35, 442-449.	8.7	134
647	MR Quantitative Susceptibility Imaging for the Evaluation of Iron Loading in the Brains of Patients with α -Thalassemia Major. American Journal of Neuroradiology, 2014, 35, 1085-1090.	2.4	36
648	Efficacy and Safety of Deferasirox in β^2 -Thalassemia Major Patients in Iran: A Prospective Study from a Single referral Center in Iran. Pediatric Hematology and Oncology, 2014, 31, 76-86.	0.8	4
649	Clinical Pharmacology of Deferasirox. Clinical Pharmacokinetics, 2014, 53, 679-694.	3.5	33
650	Guidelines for treating iron overload in myelodysplastic syndromes: a Taiwan consensus statement. International Journal of Hematology, 2014, 100, 7-15.	1.6	7
651	Concentrations of trace elements in American alligators (Alligator mississippiensis) from Florida, USA. Chemosphere, 2014, 108, 159-167.	8.2	23
652	Combination therapy of deferiasirox and deferoxamine shows significant improvements in markers of iron overload in a patient with β^2 -thalassemia major and severe iron burden. Transfusion, 2014, 54, 646-649.	1.6	21
653	Deferasirox for managing iron overload in people with myelodysplastic syndrome. The Cochrane Library, 2014, 2014, CD007461.	2.8	9
654	The long-term efficacy and tolerability of oral deferiasirox for patients with transfusion-dependent β^2 -thalassemia in Taiwan. Annals of Hematology, 2015, 94, 1945-1952.	1.8	14
655	Reproducibility of liver iron concentration measured on a biopsy sample: A validation study in vivo. American Journal of Hematology, 2015, 90, 87-90.	4.1	8
656	Generation Mechanism of Deferoxamine Radical by Tyrosine-Tyrosinase Reaction. Analytical Sciences, 2015, 31, 911-916.	1.6	2
657	Effect of iron overload on furin expression in wild-type and β^2 -thalassemic mice. Toxicology Reports, 2015, 2, 415-422.	3.3	9

#	ARTICLE	IF	CITATIONS
658	Liver injury is associated with mortality in sickle cell disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 42, 912-921.	3.7	44
659	Quantitative susceptibility mapping in the abdomen as an imaging biomarker of hepatic iron overload. <i>Magnetic Resonance in Medicine</i> , 2015, 74, 673-683.	3.0	98
660	Targeting cancer by binding iron: Dissecting cellular signaling pathways. <i>Oncotarget</i> , 2015, 6, 18748-18779.	1.8	137
661	Functional and Structural Abnormalities in Deferoxamine Retinopathy: A Review of the Literature. <i>BioMed Research International</i> , 2015, 2015, 1-12.	1.9	41
662	Ferritin as a Risk Factor for Glucose Intolerance amongst Men and Women Originating from the Indian Subcontinent. <i>International Journal of Endocrinology</i> , 2015, 2015, 1-6.	1.5	2
663	Gradually-Deteriorating Liver Function due to Iron Overload Over Four Years after Allogeneic Stem Cell Transplantation. <i>Journal of Clinical and Experimental Hematopathology: JCEH</i> , 2015, 55, 109-112.	0.8	2
664	Zinc Chelation by a Small-Molecule Adjuvant Potentiates Meropenem Activity in Vivo against NDM-1-Producing <i>Klebsiella pneumoniae</i> . <i>ACS Infectious Diseases</i> , 2015, 1, 533-543.	3.8	50
665	Reference method for measurement of the hepatic iron concentration. <i>American Journal of Hematology</i> , 2015, 90, 85-86.	4.1	5
666	Deferoxamine inhibits TRAIL-mediated apoptosis via regulation of autophagy in human colon cancer cells. <i>Oncology Reports</i> , 2015, 33, 1171-1176.	2.6	22
667	Automated interventricular septum segmentation for black-blood myocardial T2* measurement in thalassemia. <i>Journal of Magnetic Resonance Imaging</i> , 2015, 41, 1242-1250.	3.4	10
668	Sustained improvements in myocardial T2* over 2 years in severely iron-overloaded patients with beta thalassemia major treated with deferasirox or deferoxamine. <i>American Journal of Hematology</i> , 2015, 90, 91-96.	4.1	43
669	Liver MRI is more precise than liver biopsy for assessing total body iron balance: a comparison of MRI relaxometry with simulated liver biopsy results. <i>Magnetic Resonance Imaging</i> , 2015, 33, 761-767.	1.8	54
670	How I treat and manage strokes in sickle cell disease. <i>Blood</i> , 2015, 125, 3401-3410.	1.4	102
671	Liver iron overload assessment by MRI R2* relaxometry in highly transfused pediatric patients: An agreement and reproducibility study. <i>Diagnostic and Interventional Imaging</i> , 2015, 96, 259-264.	3.2	27
672	Dual-Energy CT for Patients Suspected of Having Liver Iron Overload: Can Virtual Iron Content Imaging Accurately Quantify Liver Iron Content?. <i>Radiology</i> , 2015, 277, 95-103.	7.3	57
673	Impact of educational programme regarding chelation therapy on the quality of life for B-thalassemia major children. <i>Hematology</i> , 2015, 20, 297-303.	1.5	14
674	Anemia of Central Origin. <i>Seminars in Hematology</i> , 2015, 52, 321-338.	3.4	9
675	Rapid and inexpensive blood typing on thermoplastic chips. <i>Lab on A Chip</i> , 2015, 15, 4533-4541.	6.0	22

#	ARTICLE	IF	CITATIONS
676	Iron chelation and liver disease healing activity of edible mushroom (<i>Cantharellus cibarius</i>), in vitro and in vivo assays. <i>RSC Advances</i> , 2015, 5, 4804-4810.	3.6	37
677	Tandem measurements of iron and creatinine by cross injection analysis with application to urine from thalassemic patients. <i>Talanta</i> , 2015, 133, 52-58.	5.5	10
678	Determination of deferasirox plasma concentrations: do gender, physical and genetic differences affect chelation efficacy?. <i>European Journal of Haematology</i> , 2015, 94, 310-317.	2.2	19
679	Accuracy of Magnetic Resonance Imaging in Diagnosis of Liver Iron Overload: A Systematic Review and Meta-analysis. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 55-63.e5.	4.4	49
680	Increased IL-17 and TGF- β 2 serum levels in peripheral blood of patients with β 2-thalassemia major: implication for continual transfusions role in T helper17-mediated proinflammatory responses. <i>Turkish Journal of Medical Sciences</i> , 2016, 46, 749-755.	0.9	7
681	Estimation of co-integration of the relationship between blood transfusion and iron deposits in thalassemia patients and study of the effects of some physiological factors. <i>International Mathematical Forum</i> , 2016, 11, 1089-1102.	0.1	0
682	Disappearing large calcified thoracic disc herniation in a patient with thalassaemia. <i>BMJ Case Reports</i> , 2016, 2016, bcr2015213166.	0.5	7
683	Liver stiffness assessed by transient elastography in patients with β 2 thalassaemia major. <i>Annals of Hepatology</i> , 2016, 15, 410-417.	1.5	13
684	Evaluation of a new tablet formulation of deferasirox to reduce chronic iron overload after long-term blood transfusions. <i>Therapeutics and Clinical Risk Management</i> , 2016, 12, 201.	2.0	16
685	Neuroglobin, a Factor Playing for Nerve Cell Survival. <i>International Journal of Molecular Sciences</i> , 2016, 17, 1817.	4.1	23
686	Pregnancy in women with thalassemia: challenges and solutions. <i>International Journal of Women's Health</i> , 2016, Volume 8, 441-451.	2.6	42
687	Real-life experience with liver iron concentration <sc>R</sc>2 <sc>MRI</sc> measurement in patients with hemoglobinopathies: baseline data from <sc>LICNET</sc>. <i>European Journal of Haematology</i> , 2016, 97, 361-370.	2.2	9
688	Nano drug delivery systems: a new paradigm for treating metal toxicity. <i>Expert Opinion on Drug Delivery</i> , 2016, 13, 831-841.	5.0	10
689	Mechanism of the induction of endoplasmic reticulum stress by the anti-cancer agent, di-2-pyridylketone 4,4-dimethyl-3-thiosemicarbazone (Dp44mT): Activation of PERK/eIF2 β , IRE1 α , ATF6 and calmodulin kinase. <i>Biochemical Pharmacology</i> , 2016, 109, 27-47.	4.4	36
690	Synthesis, characterization and in vitro anticancer evaluations of two novel derivatives of deferasirox iron chelator. <i>European Journal of Pharmacology</i> , 2016, 781, 209-217.	3.5	14
691	Targeting the Metastasis Suppressor, N-Myc Downstream Regulated Gene-1, with Novel Di-2-Pyridylketone Thiosemicarbazones: Suppression of Tumor Cell Migration and Cell-Collagen Adhesion by Inhibiting Focal Adhesion Kinase/Paxillin Signaling. <i>Molecular Pharmacology</i> , 2016, 89, 521-540.	2.3	45
692	The Prognostic Significance of Elevated Serum Ferritin Levels Prior to Transplantation in Patients With Lymphoma Who Underwent Autologous Hematopoietic Stem Cell Transplantation (autoHSCT): Role of Iron Overload. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016, 16, S152-S158.	0.4	5
693	Thalassemia: Impact of consanguineous marriages on most prevalent monogenic disorders of humans. <i>Asian Pacific Journal of Tropical Disease</i> , 2016, 6, 837-840.	0.5	9

#	ARTICLE	IF	CITATIONS
694	Is Vitamin C Supplementation in Patients with β^0 -Thalassemia Major Beneficial or Detrimental?. Hemoglobin, 2016, 40, 293-294.	0.8	9
696	MRI Measurements of Iron Load in Transfusion-Dependent Patients: Implementation, Challenges, and Pitfalls. Pediatric Blood and Cancer, 2016, 63, 773-780.	1.5	22
697	CONIFER - Non-Interventional Study to Evaluate Therapy Monitoring During Deferasirox Treatment of Iron Toxicity in Myelodysplastic Syndrome Patients with Transfusional Iron Overload. Oncology Research and Treatment, 2016, 39, 424-431.	1.2	2
698	Patient Involvement as Experts in the Development and Assessment of a Smartphone App as a Patient Education Tool for the Management of Thalassemia and Iron Overload Syndromes. Hemoglobin, 2016, 40, 323-329.	0.8	11
699	Otologic manifestations of Fanconi anemia and other inherited bone marrow failure syndromes. Pediatric Blood and Cancer, 2016, 63, 2139-2145.	1.5	10
700	Neuroglobin: From structure to function in health and disease. Molecular Aspects of Medicine, 2016, 52, 1-48.	6.4	91
701	Hypoxia-Mimicking Nanofibrous Scaffolds Promote Endogenous Bone Regeneration. ACS Applied Materials & Interfaces, 2016, 8, 32450-32459.	8.0	57
702	Cardioprotective effects of iron chelator HAPI and ROS-activated boronate prochelator BHAPI against catecholamine-induced oxidative cellular injury. Toxicology, 2016, 371, 17-28.	4.2	14
703	Thalassemia Major: how do we improve quality of life?. SpringerPlus, 2016, 5, 1895.	1.2	20
704	Deferasirox, a novel oral iron chelator, shows antiproliferative activity against pancreatic cancer in vitro and in vivo. BMC Cancer, 2016, 16, 702.	2.6	42
705	Role of pharmacogenetics on deferasirox AUC and efficacy. Pharmacogenomics, 2016, 17, 571-582.	1.3	15
706	Effectiveness of red blood cell exchange, partial manual exchange, and simple transfusion concurrently with iron chelation therapy in reducing iron overload in chronically transfused sickle cell anemia patients. Transfusion, 2016, 56, 1707-1715.	1.6	38
707	Mugineic acid, active ingredient of wheat grass: an oral novel hexadentate iron chelator in iron overloaded diseases. Journal of Biochemistry, 2016, 160, 163-176.	1.7	2
708	Transfusional Iron Overload in a Cohort of Children with Sickle Cell Disease: Impact of Magnetic Resonance Imaging, Transfusion Method, and Chelation. Pediatric Blood and Cancer, 2016, 63, 1414-1418.	1.5	16
709	Comparison between different software programs and post-processing techniques for the MRI quantification of liver iron concentration in thalassemia patients. Radiologia Medica, 2016, 121, 751-762.	7.7	11
710	Redox cycling metals: Pedaling their roles in metabolism and their use in the development of novel therapeutics. Biochimica Et Biophysica Acta - Molecular Cell Research, 2016, 1863, 727-748.	4.1	111
711	The contribution of multiple packed red blood cell transfusions toward cardiac and liver dysfunction in pediatric patients with acute myeloid leukemia*. Leukemia and Lymphoma, 2016, 57, 2472-2475.	1.3	0
712	Changes in metabolic indices in response to whole blood donation in male subjects with normal glucose tolerance. Clinical Biochemistry, 2016, 49, 51-56.	1.9	9

#	ARTICLE	IF	CITATIONS
713	Characterization of hepatic and cardiac iron deposition during standard treatment of anaemia in haemodialysis. <i>Nephrology</i> , 2017, 22, 114-117.	1.6	19
714	Evaluation of cardiac and hepatic iron overload in thalassemia major patients with T2* magnetic resonance imaging. <i>Hematology</i> , 2017, 22, 1-7.	1.5	21
715	MRI for Quantification of Liver and Cardiac Iron in Thalassemia Major Patients: Pilot Study in Indian Population. <i>Indian Journal of Pediatrics</i> , 2017, 84, 276-282.	0.8	13
716	Late effects of blood and marrow transplantation. <i>Haematologica</i> , 2017, 102, 614-625.	3.5	126
717	Adamantyl- and other polycyclic cage-based conjugates of desferrioxamine B (DFOB) for treating iron-mediated toxicity in cell models of Parkinson's disease. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2017, 27, 1698-1704.	2.2	10
719	Pattern of complications and burden of disease in patients affected by beta thalassemia major. <i>Current Medical Research and Opinion</i> , 2017, 33, 1525-1533.	1.9	40
720	Analogues of desferrioxamine B designed to attenuate iron-mediated neurodegeneration: synthesis, characterisation and activity in the MPTP-mouse model of Parkinson's disease. <i>Metallomics</i> , 2017, 9, 852-864.	2.4	23
721	Radial Ultrashort TE Imaging Removes the Need for Breath-Holding in Hepatic Iron Overload Quantification by R2* MRI. <i>American Journal of Roentgenology</i> , 2017, 209, 187-194.	2.2	12
722	Toxicity of iron overload and iron overload reduction in the setting of hematopoietic stem cell transplantation for hematologic malignancies. <i>Critical Reviews in Oncology/Hematology</i> , 2017, 113, 156-170.	4.4	33
723	Diagnosing and preventing iron overload. <i>Hemodialysis International</i> , 2017, 21, S58-S67.	0.9	23
724	Deferasirox pharmacogenetic influence on pharmacokinetic, efficacy and toxicity in a cohort of pediatric patients. <i>Pharmacogenomics</i> , 2017, 18, 539-554.	1.3	14
726	Safety profiles of iron chelators in young patients with haemoglobinopathies. <i>European Journal of Haematology</i> , 2017, 98, 198-217.	2.2	28
727	Diagnóstico y cuantificación de la sobrecarga férrica mediante resonancia magnética. <i>Radiologia</i> , 2017, 59, 487-495.	0.5	2
728	The iron chelating agent, deferoxamine detoxifies Fe(Salen)-induced cytotoxicity. <i>Journal of Pharmacological Sciences</i> , 2017, 134, 203-210.	2.5	42
729	Iron in neurodegenerative disorders: being in the wrong place at the wrong time?. <i>Reviews in the Neurosciences</i> , 2017, 28, 893-911.	2.9	38
730	Deferasirox for managing iron overload in people with thalassaemia. <i>The Cochrane Library</i> , 2017, 2017, CD007476.	2.8	35
731	Diagnosis and quantification of the iron overload through magnetic resonance. <i>Radiologia</i> , 2017, 59, 487-495.	0.5	1
732	Current Standards of Care and Long Term Outcomes for Thalassemia and Sickle Cell Disease. <i>Advances in Experimental Medicine and Biology</i> , 2017, 1013, 59-87.	1.6	26

#	ARTICLE	IF	CITATIONS
733	Iron Binding and Iron Removal Efficiency of Desferrioxamine Based Polymeric Iron Chelators: Influence of Molecular Size and Chelator Density. <i>Macromolecular Bioscience</i> , 2017, 17, 1600244.	4.1	15
734	In vitro and in vivo assessment of EDTA-modified silica nano-spheres with supreme capacity of iron capture as a novel antidote agent. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2017, 13, 745-753.	3.3	28
735	Decorporation of Iron Metal Using Dialdehyde Cellulose-Deferoxamine Microcarrier. <i>AAPS PharmSciTech</i> , 2017, 18, 156-165.	3.3	5
736	Cardiac iron load and function in transfused patients treated with deferasirox (the <sc>MILE</sc>) Tj ETQq1 1 0.784314 rgBT /Overload	2.2	8
737	Limitations of serum ferritin to predict liver iron concentration responses to deferasirox therapy in patients with transfusionâ€dependent thalassaemia. <i>European Journal of Haematology</i> , 2017, 98, 280-288.	2.2	29
738	Effect of packaging types and storage conditions on quality aspects of dried <i>Thunbergia laurifolia</i> leaves and degradation kinetics of bioactive compounds. <i>Journal of Food Science and Technology</i> , 2017, 54, 4405-4415.	2.8	4
739	Evaluation of protein Z plasma level in beta-thalassemia major patients in Ahvaz city in Iran. <i>Frontiers in Biology</i> , 2017, 12, 442-447.	0.7	0
740	Safety and tolerability of deferasirox in pediatric hematopoietic stem cell transplant recipients: one facility's five yearsâ€™ experience of chelation treatment. <i>Oncotarget</i> , 2017, 8, 63177-63186.	1.8	11
741	Side effect of deferiprone as iron chelator in patient with thalassemia. <i>Paediatrica Indonesiana</i> , 2017, 57, 329.	0.1	0
742	MRI-based evaluation of multiorgan iron overload is a predictor of adverse outcomes in pediatric patients undergoing allogeneic hematopoietic stem cell transplantation. <i>Oncotarget</i> , 2017, 8, 79650-79661.	1.8	16
743	Quantitative analysis of hepatic iron in patients suspected of coexisting iron overload and steatosis using multiâ€echo singleâ€voxel magnetic resonance spectroscopy: Comparison with fatâ€saturated multiâ€echo gradient echo sequence. <i>Journal of Magnetic Resonance Imaging</i> , 2018, 48, 205-213.	3.4	16
744	Quantitative susceptibility mapping in combination with water-fat separation for simultaneous liver iron and fat fraction quantification. <i>European Radiology</i> , 2018, 28, 3494-3504.	4.5	27
745	Targeted Brain Delivery of Rabies Virus Glycoprotein 29-Modified Deferoxamine-Loaded Nanoparticles Reverses Functional Deficits in Parkinsonian Mice. <i>ACS Nano</i> , 2018, 12, 4123-4139.	14.6	145
746	Quantitative susceptibility mapping (QSM) minimizes interference from cellular pathology in R2* estimation of liver iron concentration. <i>Journal of Magnetic Resonance Imaging</i> , 2018, 48, 1069-1079.	3.4	50
747	Mesoporous silicate nanoparticles/3D nanofibrous scaffold-mediated dual-drug delivery for bone tissue engineering. <i>Journal of Controlled Release</i> , 2018, 279, 69-78.	9.9	109
748	Mechanism Underlying the Effectiveness of Deferiprone in Alleviating Parkinsonâ€™s Disease Symptoms. <i>ACS Chemical Neuroscience</i> , 2018, 9, 1118-1127.	3.5	21
749	Agreement between manual relaxometry and semi-automated scanner-based multi-echo Dixon technique for measuring liver T2* in a pediatric and young adult population. <i>Pediatric Radiology</i> , 2018, 48, 94-100.	2.0	18
750	Red blood cell transfusion support and management of secondary iron overload in patients with haematological malignancies in the Netherlands: a survey. <i>Vox Sanguinis</i> , 2018, 113, 152-159.	1.5	8

#	ARTICLE	IF	CITATIONS
751	Liver Iron Quantification with MR Imaging: A Primer for Radiologists. Radiographics, 2018, 38, 392-412.	3.3	124
752	Noninvasive imaging in cardiac deposition diseases. Journal of Magnetic Resonance Imaging, 2018, 47, 44-59.	3.4	6
753	Study of platelet activation, hypercoagulable state, and the association with pulmonary hypertension in children with β^2 -thalassemia. Hematology/ Oncology and Stem Cell Therapy, 2018, 11, 65-74.	0.9	18
754	Thalassaemia. Lancet, The, 2018, 391, 155-167.	13.7	512
755	Effect of iron overload on impaired fertility in male patients with transfusion-dependent beta-thalassemia. Pediatric Research, 2018, 83, 655-661.	2.3	31
756	Advances in the Chemical Biology of Desferrioxamine B. ACS Chemical Biology, 2018, 13, 11-25.	3.4	62
757	Longitudinal changes in $\langle \text{scp} \rangle \text{LIC} \langle / \text{scp} \rangle$ and other parameters in patients receiving different chelation regimens: Data from $\langle \text{scp} \rangle \text{LICNET} \langle / \text{scp} \rangle$. European Journal of Haematology, 2018, 100, 124-130.	2.2	5
758	Amino acid profile in patients with thalassemia major analyzed by liquid chromatography-tandem mass spectrometry. Journal of Physics: Conference Series, 2018, 1073, 032044.	0.4	1
759	Relationship between liver iron concentration determined by R2-MRI, serum ferritin, and liver enzymes in patients with thalassemia intermedia. Blood Research, 2018, 53, 314.	1.3	4
760	Cloning of the Bisucaberin B Biosynthetic Gene Cluster from the Marine Bacterium Tenacibaculum mesophilum, and Heterologous Production of Bisucaberin B. Marine Drugs, 2018, 16, 342.	4.6	6
761	Iron overload in myelodysplastic syndromes: Evidence based guidelines from the Canadian consortium on MDS. Leukemia Research, 2018, 74, 21-41.	0.8	21
762	How I manage medical complications of β^2 -thalassemia in adults. Blood, 2018, 132, 1781-1791.	1.4	78
763	Pediatric red cell and platelet transfusions. Transfusion and Apheresis Science, 2018, 57, 358-362.	1.0	5
764	Thalassemia Syndromes. , 2018, , 546-570.e10.		3
765	Fludarabine-based reduced toxicity yet myeloablative conditioning is effective and safe particularly in patients with high-risk thalassemia undergoing allogeneic transplantation. Pediatric Blood and Cancer, 2018, 65, e27312.	1.5	3
766	Management of cardiac hemochromatosis. Archives of Medical Science, 2018, 14, 560-568.	0.9	23
767	Lipid accumulation in human breast cancer cells injured by iron depletors. Journal of Experimental and Clinical Cancer Research, 2018, 37, 75.	8.6	17
768	Fluorinated Analogues of Desferrioxamine B from Precursor-Directed Biosynthesis Provide New Insight into the Capacity of DesBCD. ACS Chemical Biology, 2018, 13, 2456-2471.	3.4	11

#	ARTICLE	IF	CITATIONS
769	Biomarkers of Nutrition for Development (BOND)â€”Iron Review. <i>Journal of Nutrition</i> , 2018, 148, 1001S-1067S.	2.9	206
770	A nationwide survey of hospital-based thalassemia patients and standards of care and a preliminary assessment of the national prevention program in Sri Lanka. <i>PLoS ONE</i> , 2019, 14, e0220852.	2.5	19
771	Challenges of blood transfusions in β^0 -thalassemia. <i>Blood Reviews</i> , 2019, 37, 100588.	5.7	123
772	Matrix-dependent size modifications of iron oxide nanoparticles (Ferumoxytol) spiked into rat blood cells and plasma: Characterisation with TEM, AF4-UV-MALS-ICP-MS/MS and sILCP-MS. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2019, 1124, 356-365.	2.3	24
773	Deferoxamine: An Angiogenic and Antioxidant Molecule for Tissue Regeneration. <i>Tissue Engineering - Part B: Reviews</i> , 2019, 25, 461-470.	4.8	65
774	Acceleration of chemical shift encoding-based water fat MRI for liver proton density fat fraction and T2* mapping using compressed sensing. <i>PLoS ONE</i> , 2019, 14, e0224988.	2.5	12
775	Comparative Genomics and Metabolomics Analyses of Clavulanic Acid-Producing <i>Streptomyces</i> Species Provides Insight Into Specialized Metabolism. <i>Frontiers in Microbiology</i> , 2019, 10, 2550.	3.5	20
776	Effect of phlebotomy versus oral contraceptives containing cyproterone acetate on the clinical and biochemical parameters in women with polycystic ovary syndrome: a randomized controlled trial. <i>Journal of Ovarian Research</i> , 2019, 12, 78.	3.0	8
777	Targeted Co-delivery of the Iron Chelator Deferoxamine and a HIF1 α Inhibitor Impairs Pancreatic Tumor Growth. <i>ACS Nano</i> , 2019, 13, 2176-2189.	14.6	46
778	Patents on Quantitative Susceptibility Mapping (QSM) of Tissue Magnetism. <i>Recent Patents on Biotechnology</i> , 2019, 13, 90-113.	0.8	4
779	β -Lipoic Acid Reduces Iron-induced Toxicity and Oxidative Stress in a Model of Iron Overload. <i>International Journal of Molecular Sciences</i> , 2019, 20, 609.	4.1	37
780	Hematologic improvement with iron chelation therapy in myelodysplastic syndromes: Clinical data, potential mechanisms, and outstanding questions. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 141, 54-72.	4.4	18
781	Exploiting Cancer Metal Metabolism using Anti-Cancer Metal- Binding Agents. <i>Current Medicinal Chemistry</i> , 2019, 26, 302-322.	2.4	19
782	Single-center retrospective study of the effectiveness and toxicity of the oral iron chelating drugs deferiprone and deferasirox. <i>PLoS ONE</i> , 2019, 14, e0211942.	2.5	29
783	Biexponential R2* relaxometry for estimation of liver iron concentration in children: A better fit for high liver iron states. <i>Journal of Magnetic Resonance Imaging</i> , 2019, 50, 1191-1198.	3.4	5
784	Analogues of desferrioxamine B (DFOB) with new properties and new functions generated using precursor-directed biosynthesis. <i>BioMetals</i> , 2019, 32, 395-408.	4.1	8
785	Linking the low-density lipoprotein receptor-binding segment enables the therapeutic 5 α -YHEDA peptide to cross the blood-brain barrier and scavenge excess iron and radicals in the brain of senescent mice. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2019, 5, 717-731.	3.7	10
786	Development of Neutropenic Murine Models of Iron Overload and Depletion To Study the Efficacy of Siderophore-Antibiotic Conjugates. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 64, .	3.2	13

#	ARTICLE	IF	CITATIONS
787	Cardiac and hepatic siderosis in myelodysplastic syndrome, thalassemia and diverse causes of transfusionâ€dependent anemia: the TIMES study. HemaSphere, 2019, 3, e224.	2.7	7
788	Dual-energy CT for liver iron quantification in patients with haematological disorders. European Radiology, 2019, 29, 2868-2877.	4.5	24
789	Ultrashort echo time imaging for quantification of hepatic iron overload: Comparison of acquisition and fitting methods via simulations, phantoms, and in vivo data. Journal of Magnetic Resonance Imaging, 2019, 49, 1475-1488.	3.4	6
790	Application of induced pluripotent stem cell technology for the investigation of hematological disorders. Advances in Biological Regulation, 2019, 71, 19-33.	2.3	6
791	Prospective Evaluation of an R2* Method for Assessing Liver Iron Concentration (LIC) Against FerriScan: Derivation of the Calibration Curve and Characterization of the Nature and Source of Uncertainty in the Relationship. Journal of Magnetic Resonance Imaging, 2019, 49, 1467-1474.	3.4	25
792	Ironing out the role of the cyclin-dependent kinase inhibitor, p21 in cancer: Novel iron chelating agents to target p21 expression and activity. Free Radical Biology and Medicine, 2019, 133, 276-294.	2.9	27
793	Establishment of a thalassaemia major quality improvement collaborative in Pakistan. Archives of Disease in Childhood, 2020, 105, 487-493.	1.9	6
794	Impact of treatment with iron chelation therapy in patients with lower-risk myelodysplastic syndromes participating in the European MDS registry. Haematologica, 2020, 105, 640-651.	3.5	32
795	Glucose dysregulation in patients with iron overload: is there a relationship with quantitative pancreas and liver iron and fat content measured by MRI?. European Radiology, 2020, 30, 1616-1623.	4.5	11
796	Use of drug challenge in a case of possible deferoxamine allergy. Journal of Allergy and Clinical Immunology: in Practice, 2020, 8, 1737-1739.	3.8	4
797	Azidoâ€Desferrioxamine Siderophores as Functional Clickâ€Chemistry Probes Generated in Culture upon Adding a Diazoâ€Transfer Reagent. ChemBioChem, 2020, 21, 1433-1445.	2.6	6
798	Co-inheritance of alpha globin gene deletion lowering serum iron level in female beta thalassemia patients. Molecular Biology Reports, 2020, 47, 603-606.	2.3	4
799	Evaluation of Efficacy, Safety, and Satisfaction Taking Deferasirox Twice Daily Versus Once Daily in Patients With Transfusion-Dependent Thalassemia. Journal of Pediatric Hematology/Oncology, 2020, 42, 23-26.	0.6	7
800	Wrist Joint Skeletal Changes in Children With Transfusion-dependent Thalassemia. Journal of Pediatric Orthopaedics, 2020, 40, e473-e478.	1.2	6
801	Interaction of 2,6,7-Trihydroxy-Xanthene-3-Ones with Iron and Copper, and Biological Effect of the Most Active Derivative on Breast Cancer Cells and Erythrocytes. Applied Sciences (Switzerland), 2020, 10, 4846.	2.5	9
802	Real-World Experience Measurement of Liver Iron Concentration by R2 vs. R2 Star MRI in Hemoglobinopathies. Diagnostics, 2020, 10, 768.	2.6	3
803	Determination of the R2* relaxation rate constant for estimating hepatic iron concentration: A customized approach that considers liver fat infiltration. Physica Medica, 2020, 76, 150-158.	0.7	2
804	Enabling routine Î²-thalassemia Prevention and Patient Management by scalable, combined Thalassemia and Hemochromatosis Mutation Analysis. BMC Medical Genetics, 2020, 21, 108.	2.1	2

#	ARTICLE	IF	CITATIONS
805	Pearls and Pitfalls of Metabolic Liver Magnetic Resonance Imaging in the Pediatric Population. <i>Seminars in Ultrasound, CT and MRI</i> , 2020, 41, 451-461.	1.5	1
806	Consequences of parenteral iron-dextran loading investigated in minipigs. A new model of transfusional iron overload. <i>Blood Cells, Molecules, and Diseases</i> , 2020, 83, 102440.	1.4	3
807	Highly chelating stellate mesoporous silica nanoparticles for specific iron removal from biological media. <i>Journal of Colloid and Interface Science</i> , 2020, 579, 140-151.	9.4	19
808	Potential Mechanisms Underlying the Hepaticâ€œProtective Effects of Danshensu on Iron Overload Mice. <i>Biological and Pharmaceutical Bulletin</i> , 2020, 43, 968-975.	1.4	18
809	Action of iron chelator on intramyocardial hemorrhage and cardiac remodeling following acute myocardial infarction. <i>Basic Research in Cardiology</i> , 2020, 115, 24.	5.9	29
810	Iron and hepcidin mediate human colorectal cancer cell growth. <i>Chemico-Biological Interactions</i> , 2020, 319, 109021.	4.0	33
811	Impact of MRI technique on clinical decision-making in patients with liver iron overload: comparison of FerriScan- versus R2*-derived liver iron concentration. <i>European Radiology</i> , 2020, 30, 1959-1968.	4.5	4
812	Genome-wide transcriptomics leads to the identification of deregulated genes after deferasirox therapy in low-risk MDS patients. <i>Pharmacogenomics Journal</i> , 2020, 20, 664-671.	2.0	3
813	Complex confounder-corrected R2* mapping for liver iron quantification with MRI. <i>European Radiology</i> , 2021, 31, 264-275.	4.5	20
814	The impact of COVID-19 on transfusion-dependent thalassemia patients of Karachi, Pakistan: A single-center experience. <i>Transfusion Clinique Et Biologique</i> , 2021, 28, 60-67.	0.4	9
815	Neuroglobin and neuroprotection: the role of natural and synthetic compounds in neuroglobin pharmacological induction. <i>Neural Regeneration Research</i> , 2021, 16, 2353.	3.0	12
816	Mechanisms of Intranasal Deferoxamine in Neurodegenerative and Neurovascular Disease. <i>Pharmaceuticals</i> , 2021, 14, 95.	3.8	27
817	Review article on Thalassemia. <i>Medico Research Chronicles</i> , 2021, 8, 42-46.	0.0	1
818	Quantitative T2* imaging of iron overload in a non-dedicated center â€œ Normal variation, repeatability and reader variation. <i>European Journal of Radiology Open</i> , 2021, 8, 100357.	1.6	3
819	The Psychosocial and Financial Ramifications of Thalassemia on Parents of Thalassemic Children Presented at Tertiary Care Hospitals. <i>Open Journal of Pediatrics</i> , 2021, 11, 379-387.	0.1	1
820	Evaluation of iron overload by cardiac and liver T2* in Î²-thalassemia: Correlation with serum ferritin, heart function and liver enzymes. <i>Journal of Cardiovascular and Thoracic Research</i> , 2021, 13, 54-60.	0.9	8
821	Red Blood Cell Exchange in a Patient With Extramedullary Hematopoiesis and Cor Pulmonale Secondary to Beta Thalassemia. <i>Cureus</i> , 2021, 13, e13638.	0.5	1
822	Siderophores for medical applications: Imaging, sensors, and therapeutics. <i>International Journal of Pharmaceutics</i> , 2021, 597, 120306.	5.2	25

#	ARTICLE	IF	CITATIONS
823	The Importance of Cardiac T2* Magnetic Resonance Imaging for Monitoring Cardiac Siderosis in Thalassemia Major Patients. <i>Tomography</i> , 2021, 7, 130-138.	1.8	7
824	Iron-Driven Alterations on Red Blood Cell-Derived Microvesicles Amplify Coagulation during Hemolysis via the Intrinsic Tenase Complex. <i>Thrombosis and Haemostasis</i> , 2022, 122, 080-091.	3.4	3
825	Parkinson's disease: Alterations in iron and redox biology as a key to unlock therapeutic strategies. <i>Redox Biology</i> , 2021, 41, 101896.	9.0	75
826	A RETROSPECTIVE LONG-TERM STUDY ON AGE AT MENARCHE AND MENSTRUAL CHARACTERISTICS IN 85 YOUNG WOMEN WITH TRANSFUSION-DEPENDENT Î-THALASSEMIA (TDT) BORN BETWEEN 1965 AND 1995. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2021, 13, e2021040.	1.3	2
827	Iron-Driven Alterations on Red Blood Cell-Derived Microvesicles Amplify Coagulation during Hemolysis via the Intrinsic Tenase Complex. <i>Thrombosis and Haemostasis</i> , 2021, , .	3.4	3
828	Visual electrophysiology in the assessment of toxicity and deficiency states affecting the visual system. <i>Eye</i> , 2021, 35, 2344-2353.	2.1	6
829	Regulation of iron-uptake systems in <i>Vibrio vulnificus</i> , a ferrophilic bacterium. <i>Medical Biological Science and Engineering</i> , 2021, 4, 69-82.	0.2	1
830	Subclinical atherosclerotic predictive value of inflammatory markers in thalassemia intermedia patients. <i>Expert Review of Hematology</i> , 2021, 14, 669-677.	2.2	1
831	NON-INVASIVE DIAGNOSIS AND FOLLOW-UP OF HYPERFERRITINAEMIA. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2021, 46, 101762.	1.5	1
832	Recommendations on hematopoietic stem cell transplantation for patients with DiamondâBlackfan anemia. On behalf of the Pediatric Diseases and Severe Aplastic Anemia Working Parties of the EBMT. <i>Bone Marrow Transplantation</i> , 2021, 56, 2956-2963.	2.4	9
833	Evaluation of Biosorption Capacity of Methylglycinediacetic Acid Modified Pericarp of <i>Gossypium herbaceum</i> L. for Cadmium (II) Removal from Aqueous Solution. <i>Iarjset</i> , 2021, 8, .	0.0	0
834	The Oncogenic Signaling Disruptor, NDRG1: Molecular and Cellular Mechanisms of Activity. <i>Cells</i> , 2021, 10, 2382.	4.1	29
835	Pathomechanisms of Immunological Disturbances in Î ² -Thalassemia. <i>International Journal of Molecular Sciences</i> , 2021, 22, 9677.	4.1	14
836	Multifunctional Pt(IV) prodrug candidates featuring the carboplatin core and deferoxamine. <i>Dalton Transactions</i> , 2021, 50, 8167-8178.	3.3	9
838	Some Unfavourable Effects of Transfusion. , 0, , 666-700.		6
839	Lower limit of iron quantification using dualâenergy CT â a phantom study. <i>Journal of Applied Clinical Medical Physics</i> , 2021, 22, 299-307.	1.9	3
840	Deferiprone, an oral iron chelator, ameliorates experimental colitis and gastric ulceration in rats. <i>Inflammatory Bowel Diseases</i> , 0, 5, 253-261.	1.9	2
841	Pyridoxal Isonicotinoyl hydrazone and its analogues. <i>Advances in Experimental Medicine and Biology</i> , 2002, 509, 205-229.	1.6	32

#	ARTICLE	IF	CITATIONS
842	Results of Long Term Iron Chelation Treatment with Deferoxamine. <i>Advances in Experimental Medicine and Biology</i> , 2002, 509, 91-125.	1.6	30
843	Long Term Deferiprone Chelation Therapy. <i>Advances in Experimental Medicine and Biology</i> , 2002, 509, 127-139.	1.6	4
845	Myelodysplastic Syndromes (MDS). , 2010, , 153-222.		4
846	The Clinical Application of Ozonotherapy. , 2010, , 97-232.		11
847	Congenital bone marrow failure syndromes. <i>British Journal of Haematology</i> , 2000, 111, 30-42.	2.5	31
848	Venous thromboembolism and hypercoagulability in splenectomized patients with thalassaemia intermedia. <i>British Journal of Haematology</i> , 2000, 111, 467-473.	2.5	244
849	Oral iron chelation therapy for thalassaemia: an uncertain scene. Annotation. <i>British Journal of Haematology</i> , 2000, 111, 2-5.	2.5	40
850	Continuous desferrioxamine infusion by an infusor in thalassaemia major. <i>Acta Paediatrica, International Journal of Paediatrics</i> , 1999, 88, 550-552.	1.5	6
851	Benefits and Complications of Regular Blood Transfusion in Patients with Beta-Thalassaemia major. <i>Vox Sanguinis</i> , 2000, 79, 129-137.	1.5	28
852	Metal Chelators Coupled with Nanoparticles as Potential Therapeutic Agents for Alzheimer's Disease. <i>Journal of Nanoneuroscience</i> , 2009, 1, 42-55.	0.5	34
853	Long-Term Trial of Deferiprone in 51 Transfusion-Dependent Iron Overloaded Patients. <i>Blood</i> , 1998, 91, 295-300.	1.4	4
854	A Multicenter Prospective Study on the Risk of Acquiring Liver Disease in Anti-“Hepatitis C Virus Negative Patients Affected From Homozygous β^0 -Thalassemia. <i>Blood</i> , 1998, 92, 3460-3464.	1.4	2
855	Severity of iron overload in patients with sickle cell disease receiving chronic red blood cell transfusion therapy. <i>Blood</i> , 2000, 96, 76-79.	1.4	8
856	Erythropoietin, iron, and erythropoiesis. <i>Blood</i> , 2000, 96, 823-833.	1.4	180
857	Siderocalin/Lcn2/NGAL/24p3 Does Not Drive Apoptosis Through Gentisic Acid Mediated Iron Withdrawal in Hematopoietic Cell Lines. <i>PLoS ONE</i> , 2012, 7, e43696.	2.5	45
858	Clinically Approved Iron Chelators Influence Zebrafish Mortality, Hatching Morphology and Cardiac Function. <i>PLoS ONE</i> , 2014, 9, e109880.	2.5	19
859	Determination of iron-overload in thalassemia by hepatic MRI and ferritin. <i>Revista Brasileira De Hematologia E Hemoterapia</i> , 2008, 30, .	0.7	8
860	Synergistic inhibitory effects of deferasirox in combination with decitabine on leukemia cell lines SKM-1, THP-1, and K-562. <i>Oncotarget</i> , 2017, 8, 36517-36530.	1.8	14

#	ARTICLE	IF	CITATIONS
861	An update on iron chelation therapy. Blood Transfusion, 2012, 10, 411-22.	0.4	164
862	ASSESSMENT OF CARDIAC IRON OVERLOAD IN MULTIPLY TRANSFUSED THALASSEMIC CHILDREN USING T2* WEIGHTED CARDIAC MAGNETIC RESONANCE. Indian Journal of Child Health, 2015, 02, 169-172.	0.1	1
863	Deferasirox for the treatment of iron overload associated with regular blood transfusions (transfusional haemosiderosis) in patients suffering with chronic anaemia: a systematic review and economic evaluation. Health Technology Assessment, 2009, 13, iii-iv, ix-xi, 1-121.	2.8	35
864	Mortality In Thalassaemic Patients From Solapur District, Maharashtra State, India. Bangladesh Journal of Medical Science, 2012, 11, 175-177.	0.2	1
865	The Relation between Serum Hepcidin, Ferritin, Hepcidin: Ferritin Ratio, Hydroxyurea and Splenectomy in Children with Î²-Thalassemia. Open Access Macedonian Journal of Medical Sciences, 2019, 7, 2434-2439.	0.2	11
866	Cost Analysis of Iron-Related Complications in a Single Institute. Korean Journal of Internal Medicine, 2009, 24, 33.	1.7	8
867	Getting the iron out: preventing and treating heart failure in transfusion-dependent thalassemia.. Cleveland Clinic Journal of Medicine, 2007, 74, 807-810.	1.3	6
868	Quality of life in thalassemia major. Journal of Postgraduate Medicine, 2008, 54, 273-275.	0.4	40
869	Effect of long-term transfusion therapy on the glycometabolic status and pancreatic beta cell function in patients with beta Thalassemia major. Journal of Family Medicine and Primary Care, 2014, 3, 119.	0.9	11
870	Early detection of cardiac involvement in thalassemia: From bench to bedside perspective. World Journal of Cardiology, 2013, 5, 270.	1.5	23
871	Iron overload in beta thalassemia major patients. International Journal of Blood Transfusion and Immunohematology, 2017, 7, 33.	0.4	11
872	Correlation between serum ferritin level and liver function tests in thalassemic patients receiving multiple blood transfusions. International Journal of Research in Medical Sciences, 2014, 2, 988.	0.1	5
873	The Association between Serum Ferritin Level, Tissue Doppler Echocardiography, Cardiac T2* MRI, and Heart Rate Recovery in Patients with Beta Thalassemia Major. Acta Cardiologica Sinica, 2016, 32, 231-8.	0.2	14
874	Antioxidant Activity and Inhibitory Effect on Oxidative DNA Damage of Ethyl Acetate Fractions Extracted from Cone of Red Pine (Pinus densiflora). Korean Journal of Plant Resources, 2016, 29, 163-170.	0.2	4
875	In vitro Studies of Iron Chelation Activity of Purified Active Ingredients Extracted from Triticum aestivum Linn. (Wheat Grass). European Journal of Medicinal Plants, 2012, 2, 113-124.	0.5	9
876	Comparative Effects of Antidiabetic Drug, Metformin and Deferoxamine, on Serum Lipids, Serum Ferritin and Endocrine Indicators of Diabetes Mellitus Complications in Streptozotocin Diabetic Rats. International Journal of Biochemistry Research & Review, 2014, 4, 536-549.	0.1	2
877	Evaluation of Hepatic Iron Overload Using a Contemporary 0.55T MRI System. Journal of Magnetic Resonance Imaging, 2022, 55, 1855-1863.	3.4	4
878	Iron Overload in Patients With Heavily Transfused Sick Cell Disease—Correlation of Serum Ferritin With Cardiac T2* MRI (CMRTools), Liver T2* MRI, and R2-MRI (Ferriscan®). Frontiers in Medicine, 2021, 8, 731102.	2.6	2

#	ARTICLE	IF	CITATIONS
879	Guidelines for the monitoring and management of iron overload in patients with haemoglobinopathies and rare anaemias. British Journal of Haematology, 2022, 196, 336-350.	2.5	11
880	Hemolytic Anemias. , 2000, , 77-95.		0
882	Terapia quelante oral com deferiprona em pacientes com sobrecarga de ferro. Revista Brasileira De Hematologia E Hemoterapia, 2003, 25, .	0.7	2
885	Susceptometric avaliation of chelation with deferoxamine. Revista Brasileira De Hematologia E Hemoterapia, 2008, 30, .	0.7	0
886	Hereditary Hemochromatosis and Iron Overload. , 2010, , 1045-1070.		0
887	The relationship between myocardial t2* and left ventricular volumetric and functional parameters in thalassemia major patients. Diagnostic and Interventional Radiology, 2011, 17, 346-51.	1.5	16
888	BÃ¢ta-thalassÃ©mie majeure : actualisation de la prise en charge en mÃ©decine bucco-dentaire. Medecine Buccale Chirurgie Buccale, 2011, 17, 51-54.	0.1	0
889	Evaluation of the efficacy and safety of deferasirox in pediatric patients who changed iron chelating agent from deferoxamine to deferasirox. Journal of Korean Society of Health-System Pharmacists, 2011, 28, 262-273.	0.1	0
891	Late Effects in Survivors After Hematopoietic Cell Transplantation in Childhood. Pediatric Oncology, 2014,, 133-169.	0.5	2
893	Comparative Effects of Antidiabetic Drug, Metformin and Deferoxamine, on the Hepatotoxic and Nephrotoxic Side Effects of Streptozotocin-induced Diabetes Mellitus in Rats. British Journal of Pharmaceutical Research, 2014, 4, 1820-1832.	0.4	0
894	The Effectiveness of Deferiprone in Thalassemia. Blood, 1997, 90, 894-894.	1.4	0
895	The Effectiveness of Deferiprone in Thalassemia. Blood, 1997, 90, 894-894.	1.4	0
896	Limitations of Magnetic Resonance Imaging in Measurement of Hepatic Iron. Blood, 1997, 90, 4736-4742.	1.4	1
897	Biliary Iron Excretion in Rats Following Treatment With Analogs of Pyridoxal Isonicotinoyl Hydrazone. Blood, 1998, 91, 4368-4372.	1.4	0
898	HBED: The Continuing Development of a Potential Alternative to Deferoxamine for Iron-Chelating Therapy. Blood, 1999, 93, 370-375.	1.4	0
899	A Prospective Study on TT Virus Infection in Transfusion-Dependent Patients With β^2 -Thalassemia. Blood, 1999, 93, 1502-1505.	1.4	2
900	Leitlinie zur Diagnostik und Therapie der sekundÃ¼berladung bei Patienten mit angeborenen AnÃ©mien (S2). , 2015, , 17.1-17.19.		3
901	ProteÃ§Ã£o do dano oxidativo hepÃ¡tico induzido por ferro pelo extrato aquoso da planta Plectranthus barbatus. Revista Brasileira De Plantas Medicinai, 2015, 17, 9-17.	0.3	2

#	ARTICLE	IF	CITATIONS
902	Study on Safety and Efficacy of Deferasirox in the treatment of Thalassemia in a South Indian Tertiary Care Hospital. Indian Journal of Pharmacy Practice, 2015, 8, 19-26.	0.1	0
903	CHAPTER 4. Treatment of Systemic Iron Overload. 2-Oxoglutarate-Dependent Oxygenases, 2016, , 106-152.	0.8	0
904	CHAPTER 7. Evaluation of Iron Overload by Non-Invasive Measurement Techniques. 2-Oxoglutarate-Dependent Oxygenases, 2016, , 213-259.	0.8	0
905	Iron Chelation Therapy for Treatment of Cardiac Hemochromatosis. Journal of Clinical & Experimental Cardiology, 2016, 07, .	0.0	0
906	STUDY OF GLUCOSE TOLERANCE IN CHILDREN WITH TRANSFUSION DEPENDENT THALASSEMIA AND ITS CORRELATION WITH SERUM FERRITIN. Journal of Evolution of Medical and Dental Sciences, 2016, 5, 1959-1962.	0.1	0
907	Antioxidant activities and inhibitory effects on oxidative DNA damage of leaf from <i>Zelkova serrata</i> with ethyl acetate fractions and hot water extracts. Journal of Applied Biological Chemistry, 2016, 59, 255-260.	0.4	1
908	Left ventricular functions and mass of the adolescents and young adults with thalassemia major: An echocardiography study. Paediatrica Indonesiana, 2006, 46, 214.	0.1	0
909	Clinical Management of a Pediatric Patient Associated with Thalassemia Major: A Case Report. CODS Journal of Dentistry, 2017, 9, 55-58.	0.2	0
910	Nonmalignant Hematologic Diseases. , 2017, , 61-96.		0
911	Thalassemia and its Management during Pregnancy. , 2017, 1, 5-17.		2
912	Growth And Puberty In Girls With B-Thalassemia Major And its Correlation With Chelation Therapy And Serum Ferritin Levels. Annals of International Medical and Dental Research, 2017, 3, .	0.0	0
913	Different Types of Complications in Patients Suffering from B-Thalassemia (Thalassemia Major). Journal of Gandhara Medical and Dental Science, 2017, 4, 28-40.	0.1	1
914	Klinik Olarak Faydalı Demir Bağılayıcı Ligandların Tasarım Özellikleri. Arsiv Kaynak Tarama Dergisi, 2017, 26, 320-320.	0.1	0
916	Cardiac Iron Overload: Correlation between MRI T2* & Two Dimensional Strain Echocardiography in Children with b-Thalassemia Major. Medical Journal of the University of Cairo Faculty of Medicine, 2018, 86, 1707-1712.	0.0	0
917	LETTER TO THE EDITOR. Journal of Zoo and Wildlife Medicine, 2018, 49, 834-836.	0.6	0
918	Comparative Study of the Endocrine Disorders of β-thalassemia Major Patients and Control Group in Duhok Province. Science Journal of University of Zakho, 2018, 6, 135-139.	0.1	1
919	Role of MGDA Modified Pods of Peltophorum Pterocarpum (DC.) K. Heyne for the Removal of Hexavalent Chromium from Aqueous Solution: A Sustainable and Economical Approach. International Journal for Research in Applied Science and Engineering Technology, 2019, 7, 198-212.	0.1	0
920	Effects of Spirulina platensis on the Improvement of Hepatorenal Toxicity Induced by Iron Oxide in Wistar Rats Using Biochemical and Histological Methods. Shiraz E Medical Journal, 2019, 20, .	0.3	1

#	ARTICLE	IF	CITATIONS
922	Health-related quality of life in children with hemoglobin E- β -thalassemia with special reference to iron overload. Indian Journal of Child Health, 2019, 6, 662-664.	0.1	0
923	Scaffold Based Search on the Desferithiocin Archetype. Mini-Reviews in Medicinal Chemistry, 2019, 19, 1564-1576.	2.4	2
925	Ischemia Modified Albumin and C-Reactive Protein in Children with β^2 -Thalassemia Major. Open Journal of Pediatrics, 2020, 10, 452-462.	0.1	0
926	Effectiveness of Deferasirox in Pediatric Thalassemia Patients: Experience from a Tertiary Care Hospital of Odisha. Indian Journal of Pharmacology, 2020, 52, 172.	0.7	5
927	Deer blood effectively improved clinical signs of anaemia in a rodent model. Animal Production Science, 2020, 60, 1351.	1.3	1
932	Evaluation of Liver Iron Content by Magnetic Resonance Imaging in Children with Acute Lymphoblastic Leukemia after Cessation of Treatment. Turkish Journal of Haematology, 2020, 37, 263-270.	0.5	2
933	Activation of STAT and SMAD Signaling Induces Hpcidin Re-Expression as a Therapeutic Target for β^2 -Thalassemia Patients. Biomedicines, 2022, 10, 189.	3.2	4
935	The management of haemoglobinopathies in pregnancy and childbirth. The Obstetrician and Gynaecologist, 2022, 24, 109-118.	0.4	1
936	Multi-echo Dixon and breath-hold T2-corrected multi-echo single-voxel MRS for quantifying hepatic iron overload in rabbits. Acta Radiologica, 2023, 64, 13-19.	1.1	3
937	Enterosorption in the Treatment of Heavy Metal Poisoning. Chemistry Journal of Moldova, 2021, 16, 9-27.	0.6	1
941	Understanding the Potential and Risk of Bacterial Siderophores in Cancer. Frontiers in Oncology, 0, 12, .	2.8	7
942	Deep Learning Staging of Liver Iron Content From Multiecho MR Images. Journal of Magnetic Resonance Imaging, 2023, 57, 472-484.	3.4	6
943	Promoting Adherence to Iron Chelation Treatment in Beta-Thalassemia Patients. Patient Preference and Adherence, 0, Volume 16, 1423-1437.	1.8	2
944	Recent perspectives of pediatric β^2 -thalassemia. Minerva Pediatrics, 2022, 74, .	0.4	0
945	Metabolomic Profiling and Molecular Networking of Nudibranch-Associated Streptomyces sp. SCSIO 001680. Molecules, 2022, 27, 4542.	3.8	7
946	Comparison of R1 ρ -Imaging between Rapid Acquisition with Relaxation Enhancement (RARE) and Ultrashort TE (UTE) Sequence in the Assessment of Rat Liver Iron Overload at 11.7T. Current Medical Imaging, 2022, 18, .	0.8	0
947	Multicenter Reproducibility of Liver Iron Quantification with 1.5-T and 3.0-T MRI. Radiology, 2023, 306, .	7.3	12
948	Hemoglobinopathies in Perinatal Medicine: Challenges in Management. Donald School Journal of Ultrasound in Obstetrics and Gynecology, 2022, 16, 222-237.	0.3	0

#	ARTICLE	IF	CITATIONS
949	Grade of liver siderosis in beta-thalassaemia major patients receiving different amount of blood transfusion. IMC Journal of Medical Science, 0, , 1-5.	0.4	0
950	Diagnosis and treatment of transfusion-related iron overload. Journal of the Korean Medical Association, 2022, 65, 662-672.	0.3	1
952	Iron Deprivation by Oral Deferoxamine Application Alleviates Acute Campylobacteriosis in a Clinical Murine Campylobacter jejuni Infection Model. Biomolecules, 2023, 13, 71.	4.0	4
953	Transferrin Receptor-Mediated Iron Uptake Promotes Colon Tumorigenesis. Advanced Science, 2023, 10, .	11.2	4
954	The role of the NDRG1 in the pathogenesis and treatment of breast cancer. Biochimica Et Biophysica Acta: Reviews on Cancer, 2023, 1878, 188871.	7.4	7
955	Iron chelation therapy. European Journal of Haematology, 2023, 110, 490-497.	2.2	11
956	Quantification of Liver Iron Overload with MRI: Review and Guidelines from the ESGAR and SAR. Radiology, 2023, 307, .	7.3	21
957	QUANTITATIVE ANALYSIS OF LIVER IRON DEPOSITION BASED ON DUAL-ENERGY CT IN THALASSEMIA PATIENTS. Mediterranean Journal of Hematology and Infectious Diseases, 2023, 15, e2023020.	1.3	0
958	Thalassemia care in Nepal: In dire need of improvement. EJHaem, 0, , .	1.0	0
959	Optimized serum ferritin prediction of iron overload in transfusion-dependent thalassemia: likelihood ratio and age-adjustment approach. Annals of Saudi Medicine, 2023, 43, 90-96.	1.1	0
960	Cardiac complications in thalassemia throughout the lifespan: Victories and challenges. Annals of the New York Academy of Sciences, 2023, 1530, 64-73.	3.8	0
961	A short-TR single-echo spin-echo breath-hold method for assessing liver T2. Magnetic Resonance Materials in Physics, Biology, and Medicine, 2024, 37, 101-113.	2.0	0
962	Rosmarinic Acid Liposomes Downregulate Hepcidin Expression via BMP6-SMAD1/5/8 Pathway in Mice with Iron Overload. Applied Biochemistry and Biotechnology, 0, , .	2.9	0
963	Audiologic and vestibular assessment in children and adolescents with transfusion dependent beta thalassemia major: The era of deferasirox film coated tablet. International Journal of Pediatric Otorhinolaryngology, 2024, 177, 111868.	1.0	0
964	Choroid plexus and pituitary gland hemochromatosis induced by transfusional iron overload: Two case reports. Radiology Case Reports, 2024, 19, 1666-1670.	0.6	0
965	Preparatory work for the update of the tolerable upper intake levels for iron. EFSA Supporting Publications, 2024, 21, .	0.7	0
966	Association between serum ferritin level and risk of type 2 diabetes mellitus. AIP Conference Proceedings, 2024, , .	0.4	0
967	Quantification of Liver Iron Overload with UTE Imaging. , 2023, , 535-548.		0

#	ARTICLE	IF	CITATIONS
969	A fully automatic parenchyma extraction method for MRI T2* relaxometry of iron loaded liver in transfusion-dependent patients. Magnetic Resonance Imaging, 2024, 109, 18-26.	1.8	0
970	Application of the magnetic resonance 3D multiecho Dixon sequence for quantifying hepatic iron overload and steatosis in patients with thalassemia. Magnetic Resonance Imaging, 2024, 111, 28-34.	1.8	0
971	Revisiting iron overload status and change thresholds as predictors of mortality in transfusion-dependent β^2 -thalassemia: a 10-year cohort study. Annals of Hematology, 0, , .	1.8	0